Formulation and Evaluation of Matrix Type Transdermal Patches of Benazepril Hydrochloride. by Revathi, R
FORMULATION AND EVALUATION OF MATRIX TYPE 
TRANSDERMAL PATCHES OF BENAZEPRIL 
HYDROCHLORIDE 
 
Dissertation submitted to 
THE TAMILNADU Dr.M.G.R. MEDICAL UNIVERSITY, 
CHENNAI. 
In partial fulfillment of the requirement for the award of the degree of 
 
MASTER OF PHARMACY IN PHARMACEUTICS 
 
Submitted by 
(Reg. No: 26108606) 
 
 
 
 
DEPARTMENT OF PHARMACEUTICS 
COLLEGE OF PHARMACY 
MADURAI MEDICAL COLLEGE  
MADURAI – 625 020. 
 
MAY - 2012 
Dr. Mrs. AJITHADAS ARUNA, M.Pharm., Ph. D.,  
Principal,  
College of Pharmacy, 
Madurai Medical College, 
Madurai - 625 020. 
 
 
CERTIFICATE 
 This is to certify that the dissertation entitled “FORMULATION AND 
EVALUATION OF MATRIX TYPE TRANSDERMAL PATCHES OF BENAZEPRIL 
HYDROCHLORIDE” submitted by Miss. R. REVATHI in partial fulfillment of the 
requirement for the Degree of Master of Pharmacy in Pharmaceutics is a                        
bonafide work carried out by her, under the guidance and supervision of                           
Prof. Mr. A. Abdul Hasan Sathali, M.Pharm., (Ph. D)., Professor and Head, in the 
Department of Pharmaceutics, Madurai Medical College, Madurai-20, during the academic 
year 2011 – 2012. This dissertation is forwarded to the Controller of Examination, The 
Tamilnadu Dr. M.G.R. Medical University, Chennai. 
 
 
 
 
 
 
 
Place: Madurai                                                                          (AJITHADAS ARUNA) 
Date:  
 
 
Prof. Mr. A. Abdul Hasan Sathali, M.Pharm., (Ph. D).,  
Professor & Head, 
Department of Pharmaceutics, 
College of Pharmacy, 
Madurai Medical College, 
Madurai-625020. 
 
 
CERTIFICATE 
 This is to certify that the dissertation entitled “FORMULATION AND 
EVALUATION OF MATRIX TYPE TRANSDERMAL PATCHES OF BENAZEPRIL 
HYDROCHLORIDE” submitted by Miss. R. REVATHI in partial fulfillment of the 
requirement for the Degree of Master of Pharmacy in Pharmaceutics is a bonafide work 
carried out by her, under my guidance and supervision during the academic year 2011 – 2012 
in the Department of Pharmaceutics, Madurai Medical College, Madurai-20. 
 
I wish her success in all his endeavors. 
 
 
 
 
 
 
 
 
Place: Madurai                                                               (Prof. Mr. A. Abdul Hasan Sathali) 
Date:  
ACKNOWLEDGEMENT 
 
 
“I humbly dedicate this little piece of work to almighty” 
 
 
 
It is my pleasure to express my respectful regards and thanks to our dean                          
Dr. Mr. A. EDWIN JOE, M.D., F.M., B.L., Madurai Medical College, Madurai for 
providing all kinds of supportive facilities required to carry out my project work. 
\ 
It is my privilege and honour to extend my gratitude to Dr. Mrs. AJITHADAS 
ARUNA, M.PHARM, Ph.D., Principal, College of pharmacy, Madurai Medical College, 
Madurai, for her support to carry out my project work. 
 
It is my immense pleasure to express my deep sense of gratitude and heartfelt thanks 
to Prof. Mr. A. Abdul Hasan Sathali, M.Pharm., (Ph. D)., Professor and Head,  Department 
of Pharmaceutics, College of pharmacy, Madurai Medical College, Madurai, for his 
excellence in guidance, contribution and encouragement which helped me in the successful 
completion of each and every stage of my project work. 
 
With immense pleasure I record here my indebtness and hearty thanks to                
Mr. C. Pandian, M.Pharm., Mr. R. Senthil prabhu, M.Pharm., and Mrs. D. Uma 
Maheswari, M.Pharm., Department of Pharmaceutics, for his support and valuable 
suggestions throughout my work. 
  
 I also extend my thanks to our department staff Mrs. Geetha, Mrs. Mumtaj and 
Mrs.Chitravalli for their contribution throughout my project work.  
 
 I convey sincere thanks to Dr. Usha Ravikumar, M.D., Department of Pathology and 
their staffs, Madurai Medical College, Madurai, for their timely and continuous help to carry 
out the histopathological studies for my dissertation work. 
 
I take this  previlage to convey my thanks to Mrs. Manimegalai M.Sc., M.Phil., 
Technical officer USIC – Madurai Kamaraj University, for her helping to carry out FT - IR 
studies in accordance with my dissertation work.   
 
I convey my sincere thanks to JSS College of Pharmacy, Ooty,  for their help in 
carrying out the DSC studies in accordance with my dissertation work. 
 
I express my heartiest thanks to Mr. Palani B.E., and Mr. K. Saravanan B.Pharm., 
Safetab Life Science and United Scientifics for providing drugs and chemicals to carry out 
my project work. 
 
I am very much thankful to Mrs. Lavanya Anbu, Pharma Information Centre, 
Chennai, for her help in reference collections regarding my project. 
 
I extend my thanks to Dr. Jonat, M.V.S.C., Veterinary Assistant Surgeon, Central 
Animal House, Madurai Medical College, Madurai,  for his valuable assistance during 
exvivo permeation studies. 
 
I wish to acknowledge Mrs. Ramyadevi M. Pharm., & Mr. Balaji Sastra Uniiversity, 
Tanjore for his help in SEM Studies in accordance with my Dissertation work. 
 
It is pleasure to express my thanks to my friends Mr. S. Ganesan.,                           
Mr. S. Kathiravan., Mr. V. Palanivel., Mr. T. Prakash., Mr. D. Rajiv Gandhi.,                           
Mr . V. Selvaraj., Ms .T. Suganya., Ms. B. Yuganya., & Mr. J. Varun for their moral 
support. 
 
I am also very happy to extend my thanks to my seniors Ms. A. Gokila.,                    
Mrs. R. Kavitha., Ms. K. Priyanka., Ms. P. Shangmugapriya., Ms.T. Sangeetha.,                          
Mr. R. Anbhazagan., Mr. Muthuramalingam., Mr. Jeyasuresh., and Mrs. Magudeswari for 
their moral support. 
 
I would like to give my sincere thanks to my juniors Ms. C. Deepa., Ms. M. Gomathi.,  
Ms. V.Susila devi., Mrs. J. Jayalakshmi., Ms N.Surya devi., Ms. N. Nisha., Mr. L. Magesh 
Kumar., Mr. I. Semdurai.,  Mr. P.Mainkandan.,& Mr. M. Gopinath for their timely help 
and co-operation. 
 
I also extend my thanks to all the staff members and P.G. Students of Department of 
Pharmaceutical Chemistry and Pharmacognosy for their Co-operation. 
 
I honestly acknowledge the love, care and moral support rendered by my 
family members & friends whose part cannot be expressed in holophrastic. 
 
I am extremely thankful to the staff of Start Xerox and Penguin Xerox for their 
kind co-operation during my dissertation work.        
 
 
 
CONTENTS  
 
 
CHAPTER 
NO. 
TITLE 
PAGE 
NO. 
I INTRODUCTION 1 
II 
A REVIEW ON TRANSDERMAL  DRUG DELIVERY 
SYSTEM 
6 
III LITERATURE REVIEW 28 
IV AIM & OBJECTIVE  44 
V PLAN OF WORK 46 
VI MATERIALS AND EQUIPMENTS 48 
VII DRUG PROFILE 51 
VIII EXCIPIENTS PROFILE 57 
IX EXPERIMENTAL DETAILS 71 
X 
RESULTS AND DISCUSSION 
TABLES & FIGURES 
83 
XI 
SUMMARY AND CONCLUSION 
102 
 
REFERENCES 
 
 
ANNEXURE 
 
 
       
CHAPTER I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
CHAPTER II 
 
 
 
 
 
 
 
 
 
 
 
 
 
A REVIEW ON 
TRANSDERMAL DRUG 
DELIVERY SYSTEM  
 
CHAPTER III 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  LITERATUREREVIEW  
CHAPTER IV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM AND OBJECTIVE  
CHAPTER V 
 
 
 
 
 
 
 
 
                 PLAN OF WORK 
CHAPTER VI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND 
EQUIPMENTS 
 
CHAPTER VII 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                DRUG PROFILE
CHAPTER VIII 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          EXCIPIENTS PROFILE 
CHAPTER IX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EXPERIMENTAL   DETAILS 
CHAPTER X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS AND 
DISCUSSION 
 
CHAPTER XI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY AND 
CONCLUSION 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES  
  
 
 
                 
               
 
ANNEXURE 
 
DED
MY
P
 
 
ICATED TO
 BELOVED
ARENTS 
 
 
 
 
CHAPTER I                                                                                                               INTRODUCTION 
 
 PAGE 1 
 
 
CHAPTER I 
INTRODUCTION 
A drug is any substance or product that is used or is intended to be used to modify or 
explore physiological systems or pathological states for the benefit of the recipient                    
(Tripathi K.D., 2004) 
ROUTES OF DRUG ADMINISTRATION (Tripathi K.D., 2004) 
Local routes 
 Topical  
 Deeper Tissues 
 Arterial supply 
Systemic routes 
 Oral 
 Sublingual or buccal 
 Rectal 
 Cutaneous – Transdermal therapeutic systems 
 Inhalation 
 Nasal 
 Parenteral 
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DRUG DELIVERY SYSTEM 
For many decades treatment of an acute disease or a chronic illness has been mostly 
accomplished by delivery of drugs to patients using various pharmaceutical dosage forms, 
including tablets, capsules, pills, suppositories, creams, ointments, liquids, aerosols, and 
injectables, as drug carriers. This type of drug delivery system is known to provide a prompt 
release of drug. Therefore, to achieve as well as to maintain the drug concentration within the 
therapeutically effective range needed for treatment, it is often necessary to take this type of drug 
delivery system several times a day. This results in a significant fluctuation in drug levels. They 
have resulted in the development of new techniques for drug delivery.  
These techniques are capable of controlling the rate of drug delivery, sustaining the 
duration of therapeutic activity, and/or targeting the delivery of drug to a tissue.  
 Sustained release 
  The term sustained release is known to have existed in the medical and 
pharmaceutical literature for many decades. It has been constantly used to describe a 
pharmaceutical dosage form formulated to retard the release of a therapeutic agent such that its 
appearance in the systemic circulation is delayed and/or prolonged and its plasma profile is 
sustained in duration. The onset of its pharmacologic action is often delayed, and the duration of 
its therapeutic effect is sustained. 
 Controlled release 
  The term controlled release on the other hand, has a meaning that goes byond the 
scope of sustained drug action. It also implies a predictability and reproducibility in the drug 
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release kinetics, which means that the release of drug ingredients from a controlled release drug 
delivery system proceeds at a rate profile that is not only predictable kinetically, but also 
reproducible from one unit to another (Chein Y. W., 2005). 
ADVANTAGES OF CONTROLLED DRUG DELIVERY SYSTEM  
• Decreased incidence and/or intensity of adverse effects and toxicity 
• Better drug utilization 
• Controlled rate and site of release 
• More uniform blood concentration 
• Improved patient compliance  
• Reduced dosing frequency 
• More consistant and prolonged therapeutic effect 
• A greater selectivity of pharmacological activity (Jain N. K., 2004) 
DISADVANTAGE OF CONTROLLED DRUG DELIVERY SYSTEM  
• Increase variability among dosage units 
• Stability problems 
• Toxicity due to dose dumping 
• Increased cost 
• More rapid development of tolerance 
• Need for additional patient education and counseling (Jain N. K., 2004) 
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REQUIREMENTS OF CONTROLLED DRUG DELIVERY SYSTEM  
• Extended drug action at a predetermined rate 
• Localize the drug action 
• Target drug action 
• Therapeutically based drug release (Remington., 2006) 
FACTORS GOVERNING THE DESIGN OF CONTROLLED RELEASE DOSAGE 
FORMS  
 Drug related 
  Aqueous solubility 
  Partition coefficient 
  Molecular size  
  Protein binding 
 Biological 
  Absorption 
  Distribution 
  Excretion 
  Duration of action 
  Margin of safety 
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  Side effects 
 Physiological 
  Prolonged drug absorption 
  Variability in gastro intestinal emptying and motility 
  Gastro intestinal blood flow 
 Pharmacokinetic 
  First pass metabolism 
  Variability in urinary pH 
  Enzyme induction/inhibition (Vyas S.P. and Roop K. Khar. 2008) 
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CHAPTER II 
A REVIEW ON TRANSDERMAL DRUG DELIVERY SYSTEM 
Transdermal drug delivery systems are defined as self-contained, discrete dosage 
forms which, when applied to the intact skin, deliver the drug(s), through the skin, at a 
controlled rate to the systemic circulation (Monkhouse and Huq, 1988). 
FDA approved the first transdermal patch products in 1981. These delivery systems 
provided the controlled systemic absorption of scopolamine for the prevention of motion 
sickness (TransdermScop, ALZA Corp.) and nitroglycerine for the prevention of angina 
pectoris associated with coronary artery disease (Transderm‐Nitro). Over the last two 
decades, more than 35 transdermal products have been approved generating sales of $3.2 
billion in 2002, which is predicted to rise to $4.5 billion in 2008. More recently, such dosage 
forms have been developed and/or modified in order to enhance the driving force of drug 
diffusion (thermodynamic activity) and/or increase the permeability of the skin. These 
approaches include the use of penetration enhancers, supersaturated systems, prodrugs, 
liposomes and other vesicles (Bhavna yadav et al., 2011). 
ADVANTAGES OF TRANSDERMAL DRUG DELIVERY SYSTEM (TDDS) 
Transdermal drug delivery systems offer several important advantages over more 
traditional approaches, including (Sampath kumar K.P. et al., 2010) 
• Longer duration of action resulting in a reduction in dosing frequency 
• Increased convenience to administer drugs which would otherwise require frequent 
dosing 
• Improved bioavailability 
• More uniform plasma levels 
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• Reduced side effects and improved therapy due to maintenance of plasma levels up to 
the end of the dosing interval 
• Flexibility of terminating the drug administration by simply removing the patch from 
the skin 
• Improved patient compliance and comfort via non-invasive, painless and simple 
application  
LIMITATIONS OF TRANSDERMAL DRUG DELIVERY SYSTEM 
 Some of the greatest disadvantages to transdermal drug delivery are                
(Sampath kumar K.P. et al., 2010) 
• Possibility that a local irritation at the site of application 
• Erythema, itching, and local edema can be caused by the drug, the adhesive, or other 
excipients in the patch formulation 
STRUCTURE OF THE SKIN 
The skin is one of the most extensive and readily accessible organs of the human 
body. It receives about one-third of the blood circulation through the body (Jain N. K., 2004). 
The skin is a very effective barrier for the permeation of most xenobiotics. Only a very little 
drug actually arrives at the site action. 
 Skin is a multilayered tissue consisting of epidermis, dermis and hypodermis as 
shown in Figure 1. 
 Stratum corneum (or) horny layer is the outermost layer of epidermis, which restricts 
the inward and outward movement of chemical substances. These are compacted, flattened, 
dehydrated and keratinized cells which are physiologically inactive. 
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Figure 1 Structure of skin 
Stratum corneum has two distinct chemical regions (Jain N. K., 2004) as shown in Figure 2  
The mass of intracellular (Transcellular) protein  
The intercellular lipoidal medium. 
 
Figure 2 Structure of stratum corneum 
The epidermis rests on the much thicker (2000 µm) dermis. The dermis essentially 
consists of about 80% proteins in a matrix of mucopolysaccharide ground substance                          
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(Jain N. K., 2004). Also contained within the dermis are lymphatics, nerves and epidermal 
appendages such as hair follicles, sebaceous glands and sweat glands. 
PERCUTANEOUS ABSORPTION 
 Percutaneous absorption involves passive diffusion of substances through the skin. 
The mechanism of permeation can involve passage through the epidermis itself 
(transepidermal absorption) or diffusion through shunts, particularly those offered by the 
relatively widely distributed hair follicles and eccrine glands (transfollicular or shunt 
pathway absorption) (Jain N. K., 2004). 
Transepidermal absorption 
Transepidermal (or Transcorneal) penetration includes intracellular and intercellular 
penetration, hydrophilic drugs generally seen to permeate through intracellular pathway. As 
stratum corneum hydrates, water accumulates near the outer surface of the protein filaments. 
Polar molecules appear to pass through this immobilized water. Non polar substances 
permeate through intercellular penetration. These molecules diffuse into the non-aqueous 
lipid matrix imbibed between the protein filaments as shown in Figure 3. 
Transfollicular (shunt pathway) absorption 
In Transappendegeal permeation (shunt pathway) the drug molecule may transverse 
through the hair follicles, the sebaceous pathway of pilosebaceous apparatus or the aqueous 
pathway of the salty sweat glands as shown in Figure 3.          
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Figure 3 Percutaneous absorption  
(1) Across the intact horny layer, 
(2) through the hair follicles with the associated sebaceous glands 
(3) via the sweat glands 
Principles of transdermal permeation 
Earlier skin was considered as an impermeable protective barrier, but later 
investigations were carried out which proved the utility of skin as a route for systemic 
administration. Skin is the most intensive and readily accessible organ of the body as only a 
fraction of millimeter of tissue separates its surface from the underlying capillary network.  
The various steps involved in transport of drug from patch to systemic circulation are as 
follows (Bhavna yadav et al., 2011) 
• Diffusion of drug from drug reservoir to stratum corneum  
• Sorption by stratum corneum and penetration through viable epidermis 
• Uptake of drug by capillary network in the dermal papillary layer 
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• Effect on target organ. 
FACTORS AFFECTING PERMEABILITY  
Physiological factors  
 Stratum corneum layer of the skin 
 Anatomic site of application on the body 
 Skin condition and disease 
 Age of the patient 
 Skin metabolism 
 Desquamation (peeling or flaking of the surface of the skin) 
 Skin irritation and sensitization 
 Race 
Formulation factors 
 Physical chemistry of transport 
 Vehicles and membrane used 
 Penetration enhancers used 
 Method of application 
 Device used 
Physicochemical properties of enhancers 
 Partition coefficient of 1 or greater is required. 
 pH value should be moderate, the flux of ionizable drugs can be affected by changes 
in pH that alter the ratio of charged and uncharged species and their transdermal 
permeability. 
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 Concentration of penetrant higher than solubility, excess solid drug functions as a 
reservoir and helps in maintaining constant drug concentration for prolonged time 
(Jalwal P et al., 2010). 
BASIC COMPONENTS OF TDDS  
 Polymer matrix / Drug reservoir 
 Drug 
 Permeation enhancers 
 Pressure sensitive adhesive (PSA) 
 Backing laminates 
 Release liner 
 Other excipients like plasticizers and solvents (Dipen M. Patel et al., 2011) 
Polymer matrix / Drug reservoir  
Polymers are the heart of TDDS, which control the release of the drug from the 
device. Polymer matrix can be prepared by dispersion of drug in liquid or solid state 
synthetic polymer base. Polymers used in TDDS should have good stability and 
compatibility with the drug and other components of the system and they should provide 
effective release of a drug throughout the device with safe status.  
The polymers used for TDDS can be classified as 
Natural polymers: e.g. cellulose derivatives, zein, gelatin, shellac, waxes, gums, 
natural rubber and chitosan etc. 
Synthetic elastomers: e.g. polybutadiene, hydrin rubber, polyisobutylene, silicon 
rubber, nitrile, acrylonitrile, neoprene, butyl rubber etc. 
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Synthetic polymers: e.g. polyvinyl alcohol, polyvinylchloride, polyethylene, 
polypropylene, polyacrylate, polyamide, polyurea, polyvinylpyrrolidone, 
polymethylmethacrylate etc. The polymers like polyethylene glycol, Eudragit, ethyl 
cellulose, polyvinylpyrrolidone and hydroxypropyl methylcellulose are used as matrix type 
TDDS. The polymers like ethylvinyl acetate, silicon rubber and polyurethane are used as rate 
controlling TDDS (Keith AD, 1983). 
Drug 
The selection of drug for TDDS is based on physicochemical properties of drug. 
Transdermal drug delivery system is much suitable for drug having (Chung SJ, 1999) 
• Extensive first pass metabolism 
• Narrow therapeutic window 
• Short half-life which causes non-compliance due to frequent dosing 
• Dose should be less (mg/day) 
• Low molecular weight (less than 500 Daltons) 
• Adequate solubility in oil and water 
• Low melting point (less than 200°C) 
Permeation enhancers 
These compounds are useful to increase permeability of stratum corneum by 
interacting with structural components of stratum corneum i.e., proteins or lipids to attain 
higher therapeutic levels of the drug (Williams AC., Barry BW, 2004). They alter the protein 
and lipid packaging of stratum corneum, thus chemically modifying the barrier functions 
leading to increased permeability (Karande P et al., 2005). 
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Some examples are 
Dimethyl sulfoxide, Propylene glycol, 2-Pyrrolidone, Isopropyl myristate, 
Laurocapram (Azone), Sodium lauryl sulfate, Sorbitan monolaurate, Pluronic, Cardamom oil, 
Caraway oil, Lemon oil, Menthol, d limonene, Linoleic acid.  
 Pressure sensitive adhesives (PSA) 
The pressure-sensitive adhesive (PSA) affixes the Transdermal drug delivery system 
firmly to the skin. It should adhere with not more than applied finger pressure, be 
aggressively and permanently tacky and exert a strong holding force. Additionally, it should 
be removable from the smooth surface without leaving a residue (Pocius AV et al., 1991) 
Adhesives must be skin-compatible, causing minimal irritation or sensitization, and 
removable without inflicting physical trauma or leaving residue. In addition, they must be 
able to dissolve drug and excipient in quantities sufficient for the desired pharmacological 
effect without losing their adhesive properties and skin tolerability.  
PSAs used in commercially available transdermal systems includes  
Polyacrylate 
Polyisobutylene 
polysiloxane 30 
Polyacrylates  
In general, all acrylic adhesives are polar in character, allowing them to absorb 
moisture readily and to maintain adhesion to wet skin. They also dissolve most drugs well, 
enabling high drug loading of polyacrylate matrices. 
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Polyisobutylenes (PIBs) 
Polyisobutylenes (PIBs), in contrast, are characterized by a low solvent capacity for 
drugs. PIBs are often used in membrane-controlled systems where the initial burst of drug 
released from the adhesive layer should be limited. PIB-based adhesives are mixtures of high 
and low molecular weight polymers, which provide cohesion and tackiness, respectively. By 
adjusting the composition of the PIB formulation, cold flow and adhesiveness can be 
customized for each system. 
Silicone 
Silicone, adhesives are characterized by low allergenicity. Similar to PIBs, silicones 
dissolve most drugs poorly and regulate tackiness and cohesion through polymer size. 
Molecular weight of silicones, however, can be hard to control during storage of              
drug-adhesive formulations, since drugs containing amine groups can catalyze further 
polymerization in silicone adhesives retaining residual silanol groups. To address this 
problem, special silicones have been developed that are rendered resistant to amine-catalyzed 
condensation through end-capping of silanol functional groups. 
Hot Melt Pressure Sensitive Adhesives (HMPSA) 
Melt to a viscosity suitable for coating, but when they are cooled they generally stay 
in a flow less state. They are thermoplastic in nature. 
• Compounded HMPSA 
• Ethylene vinyl acetate copolymers 
• Paraffin waxes 
• Low density polypropylene 
• Styrene-butadiene copolymers 
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• Ethylene-ethacrylate copolymers 
• Uncompounded HMPSA  
• Polyesters 
• Polyamides 
• Polyurethanes 
Backing laminate 
Backing materials must be flexible while possessing good tensile strength. 
Commonly used materials are; 
• polyolefin’s 
• polyesters 
• Elastomers in clear, pigmented, or metalized form 
Elastomeric materials such as low-density polyethylene conform more readily to 
skin movement and provide better adhesion than less compliant materials such as polyester. 
Backing materials should also have low water vapor transmission rates to promote increased 
skin hydration and, thus, greater skin permeability. In systems containing drug within a liquid 
or gel, the backing material must be heat-sealable to allow fluid-tight packaging of the drug 
reservoir using a process known as form-fill-seal. The most comfortable backing will be the 
one that exhibits lowest modulus or high flexibility, good oxygen transmission and a high 
moisture vapor transmission rate (Pfister WR., Hsieh DS., 1990). 
Examples of some backing materials 
• vinyl 
• polyester films  
• Polyester-polypropylene films  
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• Polypropylene resin 
• Polyethylene resin 
• Polyurethylene 
• Co Tran 9722 film 
• Ethylene-vinyl acetate 
• Aluminized plastic laminate 
Release Liner 
During storage the patch is covered by a protective liner that is removed and 
discharged immediately before the application of the patch to skin. It is therefore regarded as 
a part of the primary packaging material rather than a part of dosage form for delivering the 
drug. However, as the liner is in intimate contact with the delivery system, it should comply 
with specific requirements regarding chemical inertness and permeation to the drug, 
penetration enhancer and water. Typically, release liner is composed of a base layer which 
may be non-occlusive (e.g. paper fabric) or occlusive (e.g. polyethylene, polyvinylchloride) 
and a release coating layer made up of silicon or teflon. Other materials used for TDDS 
release liner include polyester foil and metalized laminates. 
Other excipients 
Solvents  
Solvents such as chloroform, methanol, acetone, isopropanol and dichloromethane are 
used to prepare drug reservoir. 
Plasticizers 
Plasticizers such as dibutylphthalate, triethylcitrate, polyethylene glycol and 
propylene glycol are added to provide plasticity to the transdermal patch. 
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METHODS OF PREPARATION OF TDDS 
Asymmetric TPX membrane method 
A prototype patch can be fabricated for this a heat sealable polyester film (type               
1009, 3m) with a concave of 1cm diameter will be used as the backing membrane. Drug 
sample is dispensed into the concave membrane, covered by a TPX {poly (4-methyl-1 
pentene)} asymmetric membrane, and sealed by an adhesive. [(Asymmetric TPX membrane 
preparation): These are fabricated by using the dry/wet inversion process. TPX is dissolved 
in a mixture of solvent (cyclohexane) and nonsolvent additives at 60°c to form a polymer 
solution. The polymer solution is kept at 40°C for 24 hrs and cast on a glass plate to a pre-
determined thickness with a gardner knife. After that the casting film is evaporated at 50°C 
for 30 sec, then the glass plate is to be immersed immediately in coagulation bath 
[maintained the temperature at 25°C]. After 10 minutes of immersion, the membrane can be 
removed, air dry in a circulation oven at 50°C for 12 hrs]. 
Circular teflon mould method 
Solutions containing polymers in various ratios are used in an organic solvent. 
Calculated amount of drug is dissolved in half the quantity of same organic solvent. 
Enhancers in different concentrations are dissolved in the other half of the organic solvent 
and then added. Di-N-butyl phthalate is added as a plasticizer into drug polymer solution. 
The total contents are to be stirred for 12 hrs and then poured into a circular teflon mould. 
The moulds are to be placed on a leveled surface and covered with inverted funnel to control 
solvent vaporization in a laminar flow hood model with an air speed of 0.5 m/s. The solvent 
is allowed to evaporate for 24 hrs. The dried films are to be stored for another 24 hrs at 
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25±0.5°C in a desiccators containing silica gel before evaluation to eliminate aging effects. 
The type films are to be evaluated within one week of their preparation. 
Mercury substrate method 
In this method drug is dissolved in polymer solution along with plasticizer. The above 
solution is to be stirred for 10 - 15 minutes to produce a homogenous dispersion and poured 
in to a leveled mercury surface, covered with inverted funnel to control solvent evaporation. 
By using “IPM membranes” method 
In this method drug is dispersed in a mixture of water and propylene glycol 
containing carbomer 940 polymers and stirred for 12 hrs in magnetic stirrer. The dispersion 
is to be neutralized and made viscous by the addition of triethanolamine. Buffer pH 7.4 can 
be used in order to obtain solution gel, if the drug solubility in aqueous solution is very poor. 
The formed gel will be incorporated in the IPM membrane. 
By using “EVAC membranes” method 
In order to prepare the target transdermal therapeutic system, 1% carbopol reservoir 
gel, polyethylene (PE), ethylene vinyl acetate copolymer (EVAC) membranes can be used as 
rate control membranes. If the drug is not soluble in water, propylene glycol is used for the 
preparation of gel. Drug is dissolved in propylene glycol; carbopol resin will be added to the 
above solution and neutralized by using 5% w/w sodium hydroxide solution. The drug (in gel 
form) is placed on a sheet of backing layer covering the specified area. A rate controlling 
membrane will be placed over the gel and the edges will be sealed by heat to obtain a leak 
proof device. 
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Aluminium backed adhesive film method 
Transdermal drug delivery system may produce unstable matrices if the loading dose 
is greater than 10 mg. Aluminium backed adhesive film method is a suitable one. For 
preparation of same, chloroform is choice of solvent, because most of the drugs as well as 
adhesive are soluble in chloroform. The drug is dissolved in chloroform and adhesive 
material will be added to the drug solution and dissolved. A custom made aluminium former 
is lined with aluminium foil and the ends blanked off with tightly fitting cork blocks. 
Preparation of TDDS by using Proliposomes 
The proliposomes are prepared by carrier method using film deposition technique. 
From the earlier reference drug and lecithin in the ratio of 0.1:2.0 can be used as an 
optimized one. The proliposomes are prepared by taking 5mg of mannitol powder in a        
100 ml round bottom flask which is kept at 60-70°c temperature and the flask is rotated at 
80-90 rpm and dried the mannitol at vacuum for 30 minutes. After drying, the temperature of 
the water bath is adjusted to 20-30°C. Drug and lecithin are dissolved in a suitable organic 
solvent mixture, a 0.5ml aliquot of the organic solution is introduced into the round bottomed 
flask at 37°C, after complete drying second aliquots (0.5ml) of the solution is to be added. 
After the last loading, the flask containing proliposomes are connected in a lyophilizer and 
subsequently drug loaded mannitol powders (proliposomes) are placed in a desiccator over 
night and then sieved through 100 mesh. The collected powder is transferred into a glass 
bottle and stored at the freeze temperature until characterization. 
By using free film method 
Free film of cellulose acetate is prepared by casting on mercury surface. A polymer 
solution 2% w/w is to be prepared by using chloroform. Plasticizers are to be incorporated at 
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a concentration of 40% w/w of polymer weight. Five ml of polymer solution was poured in a 
glass ring which is placed over the mercury surface in a glass petridish. The rate of 
evaporation of the solvent is controlled by placing an inverted funnel over the petridish. The 
film formation is noted by observing the mercury surface after complete evaporation of the 
solvent. The dry film will be separated out and stored between the sheets of wax paper in a 
desiccator until use. Free films of different thickness can be prepared by changing the 
volume of the polymer solution (J. Ashok kumar et al., 2009). 
TYPES OF TRANSDERMAL PATCHES  
Polymer membrane permeation-controlled TDDS 
In this system, the drug reservoir is embedded between an impervious backing layer 
and a rate controlling membrane (Figure 4). The drug releases only through the rate 
controlling membrane, which can be micro porous or non-porous. In the drug reservoir 
compartment, the drug can be in the form of a solution, suspension, or gel or dispersed in 
solid polymer matrix. On the outer surface of the polymeric membrane a thin layer of drug-
compatible, hypoallergenic adhesive polymer can be applied. The rate of drug release from 
this type of Transdermal drug delivery system can be tailored by varying the polymer 
composition, permeability coefficient and thickness of the rate controlling membrane. 
 
                   Figure 4:  Polymer membrane permeation-controlled TDDS 
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Examples 
TransdermScop (Scopolamine) for 3 days protection of motion sickness and 
TransdermNitro (Nitroglycerine) for once a day medication of angina pectoris. 
Adhesive diffusion controlled TDDS 
The drug reservoir is formed by dispersing the drug in an adhesive polymer and then 
spreading the medicated polymer adhesive by solvent casting or by melting the adhesive      
(in case of hot-melt adhesives) onto an impervious backing layer (Figure 5). The drug 
reservoir layer is then covered by a non-medicated rate controlling adhesive polymer of 
constant thickness to produce an adhesive diffusion controlling drug delivery system. 
 
Figure 5:  Adhesive diffusion controlled TDDS 
Example 
Deponit (Nitroglycerine) for once a day medication of angina pectoris. 
Matrix diffusion controlled TDDS 
The drug is dispersed homogeneously in a hydrophilic or lipophilic polymer matrix. 
This drug containing polymer disk then is fixed onto an occlusive base plate in a 
compartment fabricated from a drug-impermeable backing layer (Figure 6). Instead of 
applying the adhesive on the face of the drug reservoir, it is spread along the circumference 
to form a strip of adhesive rim. 
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Figure 6:  Matrix diffusion controlled TDDS 
Example 
Nitro Dur (Nitroglycerine) used for once a day medication of angina pectoris. 
Microreservoir controlled TDDS 
This drug delivery system is a combination of reservoir and matrix-dispersion 
systems (Figure 7). The drug reservoir is formed by first suspending the drug in an aqueous 
solution of water-soluble polymer and then dispersing the solution homogeneously in a 
lipophilic polymer to form thousands of unreachable, microscopic spheres of drug reservoirs. 
The thermodynamically unstable dispersion is stabilized quickly by immediately cross 
linking the polymer in situ. A transdermal system therapeutic system thus formed as a 
medicated disc positioned at the center and surrounded by an adhesive rim                      
(Dipen M. Patel and Kavitha K., 2010). 
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Figure 7 : Microreservoir controlled TDDS 
Example 
Nitro-dur® System (Nitroglycerin) for once a day treatment of angina pectoris. 
EVALUATION OF TRANSDERMAL PATCHES 
Transdermal patches have been developed to improve clinical efficacy of the drug 
and to enhance patient compliance by delivering smaller amount of drug at a predetermined 
rate. This makes evaluation studies even more important in order to ensure their desired 
performance and reproducibility under the specified environmental conditions                
(Bhavna Yadav et al., 2011). These studies are predictive of transdermal dosage forms and 
can be classified into following types: 
• Evaluation of adhesive 
• Physicochemical evaluation 
• In vitro drug release evaluation 
• Effect of skin uptake and metabolism 
• In vivo evaluation 
• Cutaneous toxicological evaluations 
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Evaluation of adhesive 
 Pressure sensitive adhesives are evaluated for the following properties (Jain N. K., 
2004) 
1) Peel adhesion properties 
2) Tack properties 
• Thumb tack test 
• Rolling ball tack test 
• Quick stick test ( peel tack test) 
• Probe tack test 
3) Shear strength properties 
Physicochemical evaluation (Bhavna yadav et al., 2011) 
• Physical Appearance 
• Weight variation 
• Thickness of the patch 
• Folding Endurance 
• Flatness 
• Percentage Moisture Content 
• Estimation of drug content 
In vitro drug release evaluation (Bhavna yadav et al., 2011) 
 Drug release mechanisms and kinetics are two characteristics of the dosage forms 
which play an important role in describing the drug dissolution profile from a controlled 
release dosage forms and hence there in vivo performance. The dissolution data is fitted to 
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these models and the best fit is obtained to describe the release mechanism of the drug. There 
are various methods available for determination of drug release rate of TDDS. 
• The Paddle over Disc (USP apparatus 5/ PhEur 2.9.4.1) 
This method is identical to the USP paddle dissolution apparatus, except that the 
transdermal system is attached to a disc or cell resting at the bottom of the vessel which 
contains medium at 32 ±5°C. 
• The Cylinder modified USP Basket (USP apparatus 6 / PhEur 2.9.4.3) 
This method is similar to the USP basket type dissolution apparatus, except that the 
system is attached to the surface of a hollow cylinder immersed in medium at 32 ± 5°C. 
• The reciprocating disc (USP apparatus 7) 
In this method patches attached to holders are oscillated in small volumes of medium, 
allowing the apparatus to be useful for systems delivering low concentration of drug. In 
addition paddle over extraction cell method (PhEur 2.9.4.2) may be used. 
Effect of skin uptake and metabolism 
 For studying in vitro skin uptake and metabolism of drug, a piece of full thickness 
skin (human cadaver skin) or stripped skin freshly excised from a hairless mouse, 5 – 7 week 
old, was mounted between the two compartments of each V – C permeation cell. It was 
mounted in such a way that either the stratum corneum or the dermis faced the drug solution 
and the other side of the skin was protected with impermeable aluminium foil. The 
compartment with the skin surface covered with aluminium foil remained empty. Both 
compartments were maintained isothermally at 370 C. Samples were withdrawn from 
solution compartment at predetermined times and assayed for drug and any possible 
metabolites (Jain N. K., 2004).  
CHAPTER II                                                    TRANSDERMAL DRUG DELIVERY SYSTEM 
 
PAGE 27 
 
In vivo evaluation (Bhavna yadav et al., 2011) 
• Animal models 
The most common animal species used for evaluating transdermal drug delivery 
system are mouse, hairless rat, hairless dog, hairless rhesus monkey, rabbit, guinea 
pig etc.  
• Human models 
The final stage of the development of a transdermal device involves collection of 
pharmacokinetic and pharmacodynamic data following application of the patch to human 
volunteers. Clinical trials have been conducted to assess the efficacy, risk involved, side 
effects, patient compliance etc. 
Cutaneous toxicological evaluations 
a) Contact dermatitis 
• Contact irritant dermatits 
     Ten – day primary irritation test 
Twenty – one day irritation test 
Laser Doppler 
Evaporative water loss measurements 
• Contact allergic dermatitis 
b) Growth of microorganisms 
• Localized superficial infections 
• Miliaria 
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CHAPTER III 
LITERATURE REVIEW 
Rupesh V. Chikhale et al., 2011, analyzed design, formulation and evaluation of transdermal 
drug delivery system of budesonide. In this study polymeric films containing ER L100:             
ER S 100: drug (7:3:1, 7:2:1) and EC: PVP: drug (7:3:1, 7:2:1) were selected for transdermal 
administration based on evaluation studies.  The polymeric films were prepared by mercury 
substrate method employing PEG-400 as plasticizer.  Urea and Dimethyl sulphoxide were used 
as penetration enhancer.  In vitro drug permeation, moisture absorption and water vapor 
transmission studies were carried out on these patches. 
Jia-You Fang et al., 2011, developed enhancement techniques for improving 5-amino levulinic 
acid delivery through the skin.  In this study enhancement of 5-aminolevulinic acid skin 
penetration can be achieved by physical methods, such as iontophoresis, laser, micro needles, 
ultrasound, and by adding chemical penetration enhancers such as DMSO, oleic acid, and others 
whereas some researchers used lipophilic alpha liphoic acid derivatives and different vehicles to 
improve the transdermal delivery of 5-aminolevulinic acid. 
Jatin Kumar Pruthi et al., 2011, developed and evaluated matrix type transdermal patch of 
ethinylestradiol and medroxy progesterone acetate for anti-implantation activity in female wistar 
rats. From this result they suggested that transdermal formulation aimed for postcoital 
antifertility activity has been successfully developed in female wistar rats. 
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Hoo-Kyun Choi et al., 2011, studied influence of formulation variables in transdermal drug 
delivery system containing zolmitriptan. In this study, effects of different formulation variables 
including pressure sensitive adhesive, thickness of the matrix, solvent system, inclusion of 
crystallization inhibitor, loading amount of drug and enhancers on the transdermal absorption of 
zolmitriptan were investigated. This study suggests that matrix based transdermal dosage form of 
zolmitriptan could be explored for the management of migraine. 
Venkateswara Raoj et al., 2010, developed matrix type transdermal patches of lercanidipine 
hydrochloride & analyzed physicochemical and In-vitro characterization. The purpose of the 
study was to select a suitable formulation for the development of transdermal drug delivery 
system of lercanidipine and to determine the effect of penetration enhancer, limonene on drug 
permeation. The transdermal patches were prepared by solvent evaporation technique. In 
conclusion the patches composed of Eudragit RL, HPMC (1.5:8.5) with 8% V/W limonene at 
penetration enhancer may be selected for the development of transdermal drug delivery system 
of lercanidipine for potential therapeutic use by using a suitable adhesive layer and backing 
membrane. 
Shashikant D. Barhate et al., 2010, evaluated in vitro permeation studies of indapamide from 
transdermal films.  Transdermal films were prepared by dissolving Eudragit RS100, lecuric acid, 
adipic acid, polyvinyl alcohol, sorbitol & indapamide in water.  In vitro permeation experiment 
was performed in Franz diffusion cell. Result of this study show that ER S100 & polyvinyl 
acetate in 1:2 proportions proved to be better composition for preparation of transdermal film. 
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Saphie Martel et al., 2010, analyzed physicochemical profile & invitro permeation behavior of a 
new class of non-steroidal anti-inflammatory drug candidates.  In this work lipophilicity & 
permeability profile of SA derivates were performed to evaluate their ADME properties related 
to oral or transdermal delivery.  All the tested compounds showed potential good passive 
permeation through GIT & all through percutaneous barrier which could be a way to avoid the 
first hepatic pass. 
Nerner Weitschier et al., 2010, analysed adhesion testing of transdermal matrix patches with a 
probe tack test invitro and in vivo evaluation. In this study twelve different types of polyacrylate 
pressure sensitive adhesive have been characterized using the probe tack test. In addition to                  
in vitro characterization the in vivo adhesive properties were investigated in a double blinded and 
randomized wear study by 8 volunteers for a period of 7 days of wear. The invitro data correlate 
mostly with the in vivo performance of the tested adhesive after 7 days. Accordingly probe tack 
test could be a helpful tool during the development of transdermal patches. 
Naohire Nishida et al., 2010, developed and evaluated monolithic drug in adhesive patch for 
valsartan. In this study to improve the penetration of valsartan in the patch, several chemical 
penetration enhancers were investigated by in vitro hairless mouse and Yucatan micro pig skin 
permeation studies. The plasma concentration time profile of valsartan after the patch was 
applied in human was estimated by a convolution technique. The results of the invitro Yucatan 
micro pig study, which indicated that the concentration of valsartan could be sufficient to 
produces a pharmacological effects. 
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Meenakshi Bharkatiya et al., 2010, Analysed & developed transdermal patches of metroprolol 
tartarate. In this matrix type patches were prepared by solvent casting method, employing a 
mercury substrate by using combination of ethylcellulose polyvinyl pyrolidone (PVP) & 
Eudragit RL100-PVP in different proportions.  The result showed that in vitro drug permeation 
followed Higuchi kinetics, the diffusion coefficient value indicated Fickian transport diffusion. 
Bharkatiya M et al., 2010, Designed & characterized drug free patches for transdermal 
application.  The aim of this study was to develop drug free polymeric patches using different 
polymers, to study the effect of different plasticizers on physicochemical properties of the 
patches, to explore their feasibility for transdermal application.  Result of this study showed that 
the strength & folding endurance of the patches prepared with dibutylphthalate & plasticizer was 
high compared with propylene glycol & polyethylene glycol. They concluded that plasticizers 
have a significant influence on the mechanical properties of the transdermal patches. 
Liang Fang et al., 2010, developed transdermal patches for site-specific delivery of anastazole, 
invitro & local tissue disposition evaluation.  In this study different adhesive matrixes, 
permeation enhancers & amounts of anastrazole were investigated for promoting the passage of 
anastrazole through the skin of rats in vitro.  These findings show that anastrazole transdermal 
patches are an appropriate delivery system for application to the breast tumor region for site, 
specific drug delivery to obtain a high local drug concentration. 
Gasem K. A. M et al., 2010, evaluated the effect of different enhancers on the transdermal 
permeation of insulin analog.  The results of this study lead to the conclusion that no specific 
chemical permeation enhancer (CPE) functional group are directly responsible for enhanced 
insulin permeation rather permeation enhancements is produced by molecules that exhibit 
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positive log k0/w value and possess at least one hydrogen donor or acceptor, with the exception 
of toluene among the 22 CPES considered. 
Alfons Schnitzler et al., 2010, evaluated high compliance with rotigotine transdermal patch in 
the treatment of idiopathic Parkinson’s disease. The purpose of this study was the non ergot 
dopamine against rotigotine has been formulated in a once daily transdermal patch for 24 hours 
application which ensures continuous rotigotine release over 24 hours.  This open prospective, 
non interventional study investigated compliance with the patch under clinical practice 
conditions.  In conclusion rotigotine transdermal patch was associated with high compliance in 
patients with Parkinson’s disease under clinical practice condition. 
Wael Samy et al., 2009, evaluated the mechanical properties and drug release of cross linked 
Eudragit films containing Metronidazole. From this study they conclude that increasing the 
concentration of either cohesion promoter or the plasticizer gave more significant effect on the 
mechanical properties of tested films. 
Jamakandi V G et al., 2009, formulated, characterized and evaluated matrix-type transdermal 
patches of a model antihypertensive drug. This investigation was aimed to evaluating the 
possibility of using different polymeric grades of hydroxy propyl methyl cellulose (6 cps, 15 cps, 
and k4m) for the development of transdermal drug delivery systems of nicorandil, an antianginal 
drug. They concluded that transdermal patch with HPMC 6 cps and 6%W/V DMSO as 
permeation enhancer showed maximum of the drug release and offered least resistance to the 
movement of the drug molecule due to its high hydrophilic nature and high water permeability 
value to water. 
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Shashikant D. Barhaten et al., 2009, developed transdermal drug delivery system of 
ketoprofen. In this study ketoprofen transdermal patches was prepared by mercury substrate 
method using polymer Eudragit RS100, Eudragit RL100, HPMC K100M, HPMC E5 and HPMC 
K4M, Propylene glycol and oleic acid used as a skin permeation enhancer and dibutylphalate, 
PEG 400 used as a plasticizer. From the results, the order of permeation of ketoprofen from 
different polymeric membranes was found to be ERL100: PVP > ERS100: PVP > EC > CA >  
EC: PVP > CA: PVP. The values of coefficient of correlation for zero order model suggested 
controlled release of ketoprofen from fabricated transdermal patches. 
Liang Fang et al., 2009, developed a drug in adhesive transdermal patch for s-amlodipine free 
base. The objective of this study was to develop and to evaluate a drug in adhesive transdermal 
patch for s-amlodipine. The effects of the type of adhesive and the content of permeation 
enhancers on s-amlodipine free base transport across excised rat skin were evaluated. In 
conclusion, the present data confirm the feasibility of developing s-amlodipine transdermal patch 
to provide plasma levels for 3 days in rats. 
Katerianal Brychtova et al., 2009, analyzed physico-chemical properties and penetration 
activity of alkyl -6 - (2, 5-dioxopyrolidin-1-yl) - 2- (2-oxopyrrolidin-1-yl) hexanoates as 
potential transdermal penetration enhancers.  In this study all the prepared compounds were 
analyzed using reverse phase high performance liquid chromatography method for the 
lipophilicity measurement and their lipophilicity was determined.  The relationship between the 
lipophilicity and the chemical structure of the studied compounds as were as the relationships 
between their chemical structure and transdermal penetration activity are mentioned. 
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Jianping Liu et al., 2009, developed double layer weekly sustained release transdermal patch 
containing gestodene and ethinyl estradiol.  In this study different polymeric combinations were 
used to develop polymeric films matrix type transdermal patch. Double layer TDDS could 
sustain the steady permeation fluxes of drugs for 7 days.  As sole enhancer PG could increase the 
permeation fluxes of drugs.  The result obtained suggested that double layer weekly sustained 
release matrix transdermal patch could be a promising delivery system for non-oral contraceptive 
method. 
Hussein O Ammar et al., 2009, developed polymeric matrix system for prolonged delivery of 
tramadol hydrochloride. This study focused on bioadhesion, skin tolerability, and 
pharmacodynamic evaluation. The results showed that the polymeric systems appear to be an 
attracting way enabling the tailoring of the intended formula.  
Ashu Mittal et al., 2009, formulated and evaluated monolithic matrix polymer films for 
transdermal delivery of Nitrendipine. In this study the polymeric films of nitrendipine were 
prepared by the film casting technique on mercury substrate. They were evaluated for 
physicochemical parameters invitro release and exvivo permeation. From the result they 
concluded that release of the drug from the films followed anomalous transport (0.5 < n < 1).  
Gattani S.G et al., 2008, optimized transdermal films of lovastatin. In this study, monolithic 
matrix typed transdermal films of lovastatin were prepared by film casting technique on mercury 
substrate. All the formulations containing 10 % W/W of lovastatin and 30 % W/W of Dibutyl 
phalate in chloroform. From this study, they concluded that the polymeric matrix type 
transdermal films of lovastatin prepared with different grades and ratios of polymers holds 
potential for transdermal delivery. 
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Chandra Amrish et. al., 2008, developed transdermal delivery of ketorolac. In this work, 
studies were carried out to investigate the effect of permeation enhancers on the invitro 
permeation of Ketorolac across rat skin. They concluded that a reservoir type transdermal patch 
for delivery of Ketorolac thus appear to be feasible of delivering Ketorolac across skin. 
Audra L. Stinchcomb et al., 2008, developed in vivo evaluation of a transdermal co drug of     
6-β-naltrexol linked to hydroxybupropion in hairless quinea pigs.  This study was carried out in 
order to determine percutaneous absorption of a transdermal co drug of naltrexol, 6-β-naltrexol 
hydroxybupropin co drug in hairless quinea pigs as well as to evaluate the safety of 6-β-naltrexol 
for development as a transdermal dosage form. The result of this study showed that a transdermal 
co drug of 6-β-naltrexol could be a viable alternative treatment for alcohol & opiate abuse. 
Aisha Khanum et al., 2008, prepared and evaluated of tolterodine tartarate transdermal films for 
the treatment of overactive bladder. In this study a  number of polymers such as hydroxy propyl 
methyl cellulose, carbopol-934P, and ethylcellulose were employed alone and an combination 
for the preparation of transdermal films were then evaluated for various physicochemical 
properties like physical appearance, weight variation, thickness, drug content, folding endurance 
and % elongation including in vitro release study.  The result of this study shows that the 
combination of HPMC: Carbopol - 934P (3: 1) with 30 % PG films were very flexible with high 
folding endurance and uniform drug content. 
Garrigues T.M et al., 2007, Analyzed nortriptyline hydrochloride skin absorptions and 
development of a transdermal patch. In this study the influence of propylene glycol, ethanol and 
oleic acid on nortriptyline hydrochloride penetration through human epidermis was studied in 
vitro at two different pH values (5.5 and 7.4). The results of this work showed that nortriptyline 
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hydrochloride permeates through the skin by passive diffusion; pH influence is remarkable for 
this molecule. 
Samir Mitragatri et al., 2007, analyzed synergistic effects of chemical enhancers on skin 
permeability. They report on the transport enhancing properties of mixture of an anionic 
surfactant (sodium lauroyl sarcosinate) and a non ionic surfactant (sorbitan monolaurate S (20)) 
in PBS: ethanol (1:1) solvents. Results show that increased aggregation showed resemblance to 
these that exhibited highest skin permeabilization. 
Luo Jia – bo et al., 2007, studied effects of Cinnamene enhancers on transdermal delivery of 
ligustrazine hydrochloride. In this study the effects and mechanisms of penetration promoters on 
in vitro percutaneous absorption of ligustrazine hydrochloride across hairless porcine dorsal skin 
were investigated, transdermal fluxes of ligustrazine hydrochloride through porcine skin were 
determined in vitro by Franz – type diffusion cells. The results showed that the permeation 
enhancement mechanisms of cinnamene are disordering the lipids, extracting the lipids and 
competitive hydrogen bonding between cinnamene enhancers and amides of ceramide head 
groups in stratum corneum. 
Sang Chul Shin et al., 2006, evaluated the physicochemical characteristics of quinupramine in 
the EVA matrix. In this study an attempt to determine the state of drug in the ethylvinyl acetate 
(EVA) matrix, X-ray diffraction FTIR and thermal analysis of the quinupramine EVA matrix 
were carried out and the results were compared with those of a physical mixture of quinupramine 
and EVA at the same ratio. They concluded that the physicochemical interactions between 
quinupramine and EVA might occur at the molecular level and that quniupramine was not 
crystalline in the EVA matrix. 
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Patrizia Santi et al., 2006, formulated single-layer transdermal film containing lidocaine. The 
aim of this work was to modulate the delivery of the model drug lidocaine hydrochloride from 
the transdermal film across rabbit ear skin. They evaluate the effect of drug loading of                   
film-forming polymer type, content of adhesive and plasticizer on lidocaine transport across the 
skin. They concluded that film forming polymer molecular weight had a negligible effect on 
drug permeation while its content was more effective and the choice of the adhesive seems to be 
the most important variable governing drug transport. 
Santi P et al., 2006, evaluated new transdermal bioadhesive film containing oxybutynin and 
studied Invitro permeation across rabbit ear skin. The results obtained in this study showed that 
the bioadhesive film can be a promising and innovative therapeutic system for the transdermal 
administration of oxybutynin. In this study the film was applied in occlusive conditions the 
release profiles were much higher than in non-occlusive conditions, reaching 50 % of drug 
peremeated after 24 hr compared to the commercial patch oxytrol, the film was more efficient 
suggesting that a smaller area or a lower drug loading could be employed. 
Mohd Aqil et al., 2006, evaluated In vivo characterization of monolithic matrix type transdermal 
drug delivery systems of pinacidil monohydrate. The aim of this study was to characterize 
transdermal drug delivery systems of pinacidil monohydrate in vivo by monitoring the effect of 
the transdermal drug delivery system on blood pressure of methyl prednisolone actate induced 
hypertensive rats. From this study they concluded that a single patch application of pinacidil 
transdermal drug delivery system can effectively control hypertension in rats for 2 days. 
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Srinivas et al., 2005, formulated and developed invitro and in vivo evaluation of membrane 
controlled transdermal systems of glibenclamide. In this study transdermal systems were 
prepared using drug containing carbopol gel as reservoir and ethyl cellulose, EudragitRS100, 
EudragitRL100 and Ethyl vinyl acetate. The formulations were subjected to various 
physicochemical studies, invitro drug release studies and permeation studies through mouse skin. 
Variation in drug release, permeation profile among the formulations containing different rate 
controlling membranes was observed. The present study shows that membrane controlled 
transdermal systems of glibenclamide exhibited better control of hypoglycemia and more 
effectively reversed the diabetes mellitus complications than oral glibenclamide administration in 
mice. 
Taravat Ghafourian et al., 2004, analyzed the effect of penetration enhancer on drug delivery 
through skin, a QSAR study.  In this study, the structural requirements of penetration enhancers 
have been investigated using quantitative structure activity relationship (QSAR) technique.  The 
resulting QSARS for enhancement towards different drugs incorporated different structural 
descriptors, suggesting the involvement of different mechanisms. For 5-fluorouracil & disodium, 
molecular descriptors in the corresponding QSARs indicated the possible involvement of 
intermolecular, electron donor, acceptor interactions. 
Charles M. Heard et al., 2004, developed in vitro transdermal delivery of the major catechins & 
caffeine from extract of camellia sinensis.  The aim of this study was to investigate the feasibility 
of the transdermal delivery of catechins & caffeine from green tea extract.  Transdermal delivery 
was determined across full thickness pig ear skin from saturated solutions of green tea extract in 
pH 5.5 citrophosphate buffer, PEG 400 & 50:50 mixture of citrate phosphate buffer & PEG in 
addition to patch containing 1.35mg/cm
2
.  The result indicates that the permeation from the patch 
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was within the range of Cmax plasma levels achieved after oral dosing of 2.2-4.2 gm
-2 green tea 
extract. 
Ramesh Panchanula et al., 2002, developed transdermal delivery of zidovudine and determined 
the effect of vehicles on permeation across rat skin and their mechanism of action.  The purpose 
of this study was to investigate the effects of various solvent systems containing water, ethanol, 
PG and their binary combinations on the exvivo permeation of zidovudine across spraque dawlay 
rat skin using Franz diffusion cells at 370C.  From the result they concluded that highest flux and 
short lag time were achieved with ethanol at 66.6% in water and hence it’s a suitable vehicle for 
transdermal delivery of zidovudine. 
Hassan Arabi et al., 2002, prepared transdermal delivery system and evaluated the effect of 
membrane type for scopolamine drug. In this study scopolamine hydrobromide was incorporated 
into 2 polymers and release rate across ethylene-vinyl acetate copolymers & EC membranes 
were measured.  The results showed that the rate of release increases with the increase of 
porosity size of EC surface despite of having high molecular weight. 
Stanislaw Janicki et al., 2001, developed matrix-type transdermal systems and evaluated the 
penetration of terpenes from the transdermal systems through human skin by Invitro studies. In 
this study polyurethane matrices containing upto 39 % of the terpenes, eucalyptol, L-limonene, 
D-limonene, dipentene or terpinolene were produced. From the result they concluded that 
penetration of terpenes was slower in the presence of epidermis, release and penetration through 
the epidermis and dermis were fastest for dipentene, being at least 3-4 times faster than for       
D-limonene and L-limonene.  
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Guyot M et al., 2000, developed design and invitro evaluation of adhesive matrix for 
transdermal delivery of propanolol. In this study the influence of different factors was 
investigated. The result showed that in all matrices types, propylene glycol accelerated 
propranolol release rate. 
Belal F et al., 2000, developed spectrophotometric determination of benazapril in tablets.  In this 
study a simple and sensitive spectrophotometric method has been developed for the 
determination of benazepril hydrochloride in pharmaceutical formulations.  The proposed 
method could be applied to the determination of benazepril in presence of the co formulated 
drug, hydrochlorthiazide. 
Douw G. Muller et al., 2000, Performed a comparative study of an in situ adapted diffusion cell 
and an in vitro Franz diffusion cell method for transdermal absorption of doxylamine.  The aim 
of this study was to compare the invitro Franz diffusion cell method with an in situ adapted 
diffusion cell method.  The results showed that excised skin undergoes sub-lethal injury 
(necrosis) during in vitro experiments, which may lead to increased permeability of the drug.  
Considering these advantages and the results obtained from this study, they concluded that the in 
vitro Franz diffusion cell is the method of choice for experiments on percutaneous absorption but 
care must be taken when performing studies over extended periods, since it was shown that the 
degradation of excised skin occurs. 
Riitta Sutinen et al., 1999, Analyzed water activated pH controlled patch in transdermal 
administration of timolol.  The aim of this study was to test the suitability of the patch design in 
transdermal delivery & further to select such transdermal patch formulations to a clinical study 
with timolol.  The effect of skin on drug release was evaluated in vitro with this devices both the 
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rate of drug release & the duration of constant release were controlled.  On the basis of in vitro 
data & kinetic simulations, devices of 10cm
2
 volume releasing timolol in vitro at the rates of    
10µg h
-1 
cm
2 
were selected for human tests. 
Mura P  et al., 1999, evaluated transcutol as a clonazepam transdermal permeation enhancer 
from hydrophilic gel formulations. In this study the influence of diethyleneglycol monoethyl 
ether (transcutol) alone or in combination with PG, on clonazepam permeation through an 
artificial membrane and excised rabbit ear skin from carbopol hydro gels was investigated, the 
result is explained on the basis of the particular mechanism of action demonstrated for transcutol 
which associates the increase of drug solubility to the potent effect of a depot in the skin. 
Minghetti P et al., 2000, developed local patches containing melilot extract. Two types of 
methacrylate patches were prepared.  The data of the exvivo coumarin skin permeation and those 
obtained by the in vivo stripping technique showed a good correlation.  The coumarin permeated 
across the skin in vivo correlated well with those permeated exvivo, therefore exvivo permeation 
test can be useful to predict the amount of coumarin absorbed in vivo. 
Charles M. Heard et al., 1999, evaluated the therapeutic dose of primaquine can be delivered 
across excised human skin from simple transdermal patches. This work investigated the 
permeation of primaquine across full thickness excised human skin from two acrylate 
transdermal adhesives. From this study they determined that a simple patch with a diameter        
of ≈ 13 cm2 could deliver a therapeutic in vivo dose, with possibilities for the treatment and 
prophylaxis of malaria and also concluded that the presence of migliol 840 failed to produce the 
anticipated enhancing effect. 
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Agrawal S.S et al., 1996, formulated transdermal controlled administration of verapamil 
enhancement of skin permeability.  In this study transdermal drug delivery systems of verapamil 
hydrochloride using hydrophilic polymers PVA & PVP and different concentrations of 
enhancers, d-limonene was developed. Result obtained showed that permeation rate was 
enhanced & followed approximately zero order kinetics. 
Fusun Acarture et al., 1995, investigated the effect of different adjuvant on felodipine release 
kinetics from sustained release monolithic films. The sustained release monolithic films are 
developed by employing a calcium channel blocker, felodipine, with two acrylic resin polymers 
of varying permeability. The relationship between the invitro drug release data, moisture 
permeation constant and glass transition temperature was investigated. They concluded that       
in vitro release rate of drug increased with increasing water vapor transmission and no 
relationship was established between glass transition temperature of the films and invitro release 
of drug. 
Suresh P. Vyas et al., 1989, developed effective and controlled transdermal delivery of 
ephedrine.  In this study the drug plasma profiles were compared with the plasma profile 
obtained following the administration of normal oral multiple doses of ephedrine hydrochloride 
using conventional tablets.  After transdermal application of half the doses of ephedrine, as 
compared with the conventional dose recommended for administration during 24 hours, constant 
and comparatively higher drug blood level could be achieved.  The most promising in vivo 
availability of the drug was recorded with selected pseudolatices. 
Rosilio V et al., 1988, Evaluated physico-chemical characterization of EC drug loaded cast 
films.  In this study the influence of solvent on certain physico chemical properties cast unloaded 
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& SIBA loaded EC films has been studied using chloroform, ethanol and a mixture of 
chloroform and ethanol.  The result obtained in this study have shown that the wetting properties 
and permeability of the films significantly affected by solvents.  They concluded that the effect 
of solvent is particularly significant in the case of films cast from chloroform, ethanol mixture. 
Srini N. Tenjarala et al., investigated synthesis and evaluation of N-acetyl prolinate esters novel 
skin penetration enhancers. In this study a series of N-acetyl prolinate esters (alkyl side chain 
length, 5-18) were synthesized and tested for potential skin penetration enhancement activity 
using modified Franz diffusion cells and hairless moused skin as the penetration barrier. The 
result showed that maximum flux increase was obtained with the 11 and 12 carbon (alkyl chain 
length) esters for both benazepril and hydrocortisone. The 18-carbon ester which has a             
cis-double bond in the alkyl side chain also increased the flux significantly. 
Anilreddy B.  et al., Analyzed invitro characterization and evaluation of transdermal drug 
delivery system for metoprolol tartarate transdermal films of metoprolol tartarate were prepared 
using polymers such as EC, PVA, ER L100, EL 100, DBP was used as plasticizer.  In vitro drug 
release kinetics was studied using Franz diffusion cell drug release followed zero order kinetics.  
In conclusion combination of EC, PVA, ER L100, and EL100 & DBP can potentially be 
optimized to develop an effective transdermal drug delivery system for metroprolol tartarate. 
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CHAPTER IV 
AIM AND OBJECTIVE  
The transdermal route of administration has been recognized as one of the highly 
potential routes. Transdermal drug delivery is the delivery of drugs across epidermis to achieve 
systemic effects. Transdermal patches control the delivery of drugs at controlled rates by 
employing an appropriate polymer. This route allows controlled release of the drug at rates 
approaching zero-order simulating those provided by intravenous infusion. 
The skin is one of the most extensive and readily accessible organs of the human body. It 
receives about one-third of the blood circulation through the body. Hence the skin has been 
explored as the port of entry of drugs. 
Development of transdermal drug delivery system offers a possible approach to 
overcome some of the drawback of oral therapy such as, 
a) This route improves compliance of the patient    
 b) Ensures essentially constant drug input  
c) Bypasses the gastrointestinal tract and the liver as sites of metabolism, that are 
responsible for the low oral bioavailability of drugs. 
Benazepril hydrochloride is an angiotension converting enzyme inhibitor used to treat 
hypertension, heart failure, to reduce proteinuria, renal disease in patient with nephropathies, 
prevent stroke, myocardial infarction and cardiac death in high risk patients. The extent of 
absorption is about 37%, it undergoes extensive first pass metabolism and has a short biological 
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half life (3 hours). It could be a promising candidate in transdermal system design taking into 
accounts its high lipid solubility and penetration behavior. 
The aim of this study is to develop suitable transdermal patches of benazepril 
hydrochloride by employing ethylcellulose, Eudragit S100 and Eudragit L100 as a film former 
and to investigate the effect of polymers, plasticizer and permeation enhancer on in vitro release 
of transdermal patches of benazepril hydrochloride.  
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CHAPTER V 
PLAN OF WORK 
 The plan of work involves formulation and evaluation of matrix type transdermal patches 
of benazepril hydrochloride. 
PART A 
 PREPARATION OF STANDARD CALIBRATION CURVE 
a) Preparation of dissolution medium - Phosphate buffered saline pH 7.4 
b) Preparation of calibration curve for benazepril hydrochloride 
PART B 
DRUG – POLYMER INTERACTION STUDIES  
a) FTIR study 
b) Differential Scanning Calorimetry Study 
PART C 
FORMULATION OF BENAZEPRIL HCL TRANSDERMAL PATCHES 
a) Formulation of transdermal patches of Benazepril Hydrochloride using solvent casting 
technique. 
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PART D 
EVALUATION OF TRANSDERMAL PATCHES  
a) Physical appearance 
b) Weight variation 
c) Thickness of the films 
d) Folding endurance 
e) Flatness 
f) Percentage moisture content 
g) Estimation of drug content 
h) Invitro drug release studies 
i) Study of drug release kinetics 
j) Ex-vivo permeation studies 
k) Statistical analysis 
l) Histopathology studies 
PART E 
SCANNING ELECTRON MICROSCOPY  
a) The surface morphology of the patch before and after exvivo permeation study using 
scanning electron microscopy. 
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CHAPTER VI 
MATERIALS AND EQUIPMENTS 
MATERIALS  
1. Benazepril Hydrochloride             - Gift sample from Safe Tab Life Science,  
                                                                     Puducherry. 
2. Ethyl cellulose   - Gift sample from Safe tab Life Science,  
                                                                     Puducherry. 
3. Eudragit L100               - Gift sample from Orchid Pharmaceuticals,  
Chennai.                          
4. Eudragit S100                                     - Gift sample from Orchid Pharmaceuticals,                               
                                                              Chennai. 
5. Dibutyl phthalate   - Loba Chemis private limited, India. 
6. Poly ethylene glycol                          - Bargoyne urbidges & Co, Mumbai. 
7.   Dimethyl sulfoxide                           -         The British Drug Houses Ltd,  England. 
8.   Ethanol                                              -  Changshu Yangyuah chemicals, China. 
9. Potassium dihydrogen phosphate  - High purity laboratory chemicals, Mumbai.            
10.   Disodium hydrogen phosphate - Nice chemicals Pvt Ltd, Kerala.                                               
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11.   Sodium chloride   - Central Drug House (P) Ltd, New Delhi.    
12.  Formaldehyde solution                    -           Astron chemicals, Ahmedabad. 
13.  Surgical spirit                                   -           Tansi polish unit, Madras.. 
 
EQUIPMENTS  
1. Petri plate     - Universal Scientifics, Madurai. 
2. Electronic weighing balance  - A & D Company, Japan. 
3. Hot air oven    - RIC Scientific Research & laboratory    
                                                                        Instruments, Chennai.           
4. Vernier caliper   - Linker, India 
5. Dissolution apparatus                       -    Lab India Instruments Pvt Ltd. 
 (Lab India DS 8000)                                     Navi mumbai. 
6. Franz diffusion cell   - Universal Scientifics, Madurai. 
7. Magnetic stirrer with hot plate          -           M.C. Dalal & Co, Chennai. 
8. UV-Visible spectrophotometer - Shimadzu Corporation, Japan. 
9. Micro slides                                     -           M.C.Dalal &Co, Chennai. 
10. Scanning electron microscope - Hitachi S-3400, Japan. 
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11. FT-IR     - Shimadzu, Japan. 
12. Differential Scanning Calorimetry     -         DSC Q 200, Mumbai. 
13. Refrigerator                                        - Kelvinator, India. 
CHAPTER VII                                                                                          DRUG PROFILE 
 
PAGE 51 
 
CHAPTER VII 
DRUG PROFILE  
BENAZEPRIL HYDROCHLORIDE 
 
STRUCTURAL FORMULA 
 
 
 
SYNONYMS: 
 
Benazepril HCl 
Benazepril Hydrochloride 
Benazeprilum (Latin) (Drug Bank: Benazepril). 
 
EMPIRICAL FORMULA: 
 
C24H28N2O5, HCl 
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CHEMICAL NAME : 
 
{(3S)-3-[(1S)-1-Ethoxycarbonyl-3-phenylpropylamino]-2,3,4,5-tetrahydro- 2-oxo-1H-1-
benzazepin-1-yl}acetic acid hydrochloride; 1-Carboxymethyl-3-[1-ethoxycarbonyl-3-phenyl-
(1S)-propylamino]-2,3,4,5-tetrahydro-1H-1(3S) benzazepin-2-one hydrochloride. 
  
DESCRIPTION: 
 
Nature   : White crystalline powder 
Solubility  : Soluble in water, ethanol and methanol  
Melting point  : 148.5º 
Molecular weight : 424.49 g/mol 
pKa   : 5.3 
log P   : 3.3 
 
CHEMICAL PROPERTIES: 
 
Loss on drying            : Not more than 0.5 % W/W 
Residue on ignition     : Not more than 0.1 % W/W 
Heavy metals              : Not more than 0.001 % 
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MECHANISM OF ACTION: 
Benazepril and benazeprilate inhibit angiotensin-converting enzyme (ACE) in human 
subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin 
I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone 
secretion by the adrenal cortex.  
Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased 
vasopressor activity and to decreased aldosterone secretion. The latter decrease may result in a 
small increase of serum potassium.  
While the mechanism through which benazepril lowers blood pressure is believed to be 
primarily suppression of the renin-angiotensin-aldosterone system, benazepril has an 
antihypertensive effect even in patients with low-rennin hypertension (Drug Bank: Benazepril). 
 
PHARMACOKINETICS: 
Absorption:  
 Peak in plasma within 0.5-1.0 Hours. The extent of absorption is atleast 37% as 
determined by urinary recovery and is not significantly influenced by the presence of food  in 
the GI tract. 
Distribution in blood:  
 Benazeprilate is not extensively distributed into extravascular sites with minimum 
passage across the blood/brain barrier. 
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Metabolism:  
 Cleavage of the ester group (primarily in the liver) converts benazepril to its active 
metabolite, benazeprilate. Benazepril and benazeprilat may be conjugated to glucuronic acid 
prior to urinary excretion. 
 
Excretion: 
  Benazepril and benazeprilate are cleared predominantly by renal excretion in healthy 
subjects with normal renal function. Nonrenal (i.e., biliary ) excretion accounts for 
approximately 11%-12% of benazeprilat excretion in healthy subjects (Colin Dollery., 1999, 
Drug Bank: Benazepril). 
 
INDICATIONS AND USAGE: 
Control of arterial hypertension 
Treatment of congestive heart failure (Colin Dollery., 1999) 
 
DOSE:  
An initial dose of 10 mg once daily is recommended in patients with creatinine clearance 
≥30 ml /min and those not receiving diruetics.  
Hypertensive patients with heart failure and those with a creatinine clearance                   
≥ 30 ml /min are recommended an initial daily dose of 5 mg (Anthony C Moffat., 2004, Colin 
Dollery., 1999). 
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ADVERSE EFFECTS  
Serious Reactions 
• angioedema, head/neck 
• angioedema, intestinal 
• hypotension, severe 
• hyperkalemia 
• renal impairment/failure 
• hepatotoxicity 
• neutropenia 
• agranulocytosis 
• anemia, hemolytic 
• thrombocytopenia 
• pancreatitis 
• Stevens-Johnson syndrome 
• pemphigus 
• oligohydramnios (in utero exposure) 
• fetal/neonatal harm or death (in utero exposure) 
• congenital malformations, major (1st trimester use) 
Common Reactions 
• cough 
• hypotension 
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• dizziness 
• fatigue 
• hyperkalemia 
• nausea/vomiting 
• elevated Cr 
• musculoskeletal pain 
• photosensitivity  
DRUG INTERACTIONS: 
Potentially hazardous interactions: 
Increased hypotensive effects occur when benazepril is combined with thiazide diuretics or 
dihydropyrimidine calcium antagonist (Colin Dollery., 1999). 
 
CONTRAINDICATIONS: 
Angioedema 
Pregnancy (Colin Dollery., 1999). 
 
STORAGE: 
Preserve in well closed container store below 30º C. 
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CHAPTER VIII 
EXCIPIENTS PROFILE  
POLYMETHACRYLAT (EUDRAGIT L100)  
 
Synonyms   :  Acryl-EZE; Acryl-EZE MP; Eastacryl 30D; Eudragit                                    
                                                             KollicoatMAE 30 D; Kollicoat MAE 30 DP;  
                                                             Polymeric methacrylates. 
 
Nonproprietary names : BP:  Methacrylic acid–ethyl acrylate copolymer (1: 1) 
PhEur: Acidum methacrylicum et ethylis acrylas 
polymerisatum    (1: 1)                                                                                  
Acidum methacrylicum et ethylis acrylas polymerisatum 
(1: 1) dispersio 30 per centum 
Acidum methacrylicum et methylis methacrylas 
 (1: 1) 
Acidum methacrylicum et methylis methacrylas 
Polymerisatum (1: 2) 
Copolymerum methacrylatis butylati basicum 
Polyacrylatis dispersion 30 per centum 
USPNF:             
Ammonio methacrylate copolymer 
Methacrylic acid copolymer 
d copolymer dispersion 
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Chemical name  : Poly (methacrylic acid, methyl methacrylate) 1 : 1 
Empirical formula  : (C5 H8 O2 )n 
 
Structural formula  : 
 
           R
1
, R
3
, R
4  
= CH3 
                  R
2 
 = H 
 
Description   
 Nature   :   White free flowing powder 
 Solubility   :   Soluble in acetone and alcohol 
 Molecular weight  :  ≥ 100 000 
 
Functional categories   : Film former 
Tablet binder 
Tablet diluent 
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Properties  
Loss on drying  : ≤  5.0% 
Methyl methacrylate and                                                                                                            
methacrylic acid                      : ≤  0.1% 
Sulfated ash                             : ≤  0.1%                                               
Apparent viscosity             : 50–200 mPa s 
Stability and storage             :  Dry powders are stable for at least 3 years if stored  
      in a tightly closed container at less than 30ºC. 
Assay               : Methacrylic acid units 46.0–50.6%  
     (Raymond C. Rowe et al., 2006). 
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POLYMETHACRYLAT (EUDRAGIT S100) 
 
Synonyms   :  Acryl-EZE; Acryl-EZE MP; Eastacryl 30D; Eudragit;                                    
KollicoatMAE 30 D; Kollicoat MAE 30 DP;  
polymeric methacrylates. 
 
Nonproprietary names : BP: Methacrylic acid–ethyl acrylate copolymer (1 : 1) 
PhEur:                                                                                           
Acidum methacrylicum et ethylis acrylas polymerisatum 
(1 : 1) 
Acidum methacrylicum et ethylis acrylas polymerisatum 
(1 : 1) dispersio 30 per centum 
Acidum methacrylicum et methylis methacrylas 
Polymerisatum (1 : 1) 
Acidum methacrylicum et methylis methacrylas 
Polymerisatum (1 : 2) 
Copolymerum methacrylatis butylati basicum 
Polyacrylatis dispersion 30 per centum 
USPNF:             
Ammonio methacrylate copolymer 
Methacrylic acid copolymer 
Methacrylic acid copolymer dispersion 
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Chemical name  : Poly (methacrylic acid, methyl methacrylate) 1 : 2 
 
Empirical formula  : (C5 H8 O2) n 
 
Structural formula   
 
          R
1
, R
3
, R
4  
= CH3 
                  R
2 
= H 
 
Description     
 Nature   :   White free flowing powder 
 Solubility   : Soluble in acetone and alcohol 
 Molecular weight  : ≥ 100 000 
 
 Functional categories   : Film former 
Tablet binder 
Tablet diluents 
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Properties  
Loss on drying           :  ≤ 5.0% 
Methyl methacrylate and   
methacrylic acid                    : ≤ 0.1% 
Sulfated ash                           : ≤ 0.1%                                               
Apparent viscosity               : 50–200 mPa s 
Stablility and storage            : Dry powders are stable 
for at least 3 years if stored in a tightly closed  
container at less than 30ºC. 
Assay                                   : Methacrylic acid units 27.6–30.7% 
     (Raymond C. Rowe et al., 2006). 
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ETHYL CELLULOSE 
 
Synonyms   : Aquacoat ECD; Aqualon; E462; Ethocel; Surelease. 
 
Nonproprietary names : BP: Ethylcellulose 
PhEur: Ethylcellulosum 
USPNF: Ethylcellulose 
 
Chemical name  : Cellulose ethyl ether 
 
Empirical formula  : C12H23O6 (C12H22O5)n C12H23O5 
 
Structural formula    
     
 
Description   : Ethylcellulose is a tasteless, free-flowing, white to light   
tan colored powder. 
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 Functional categories  : Coating agent; flavoring fixative; tablet binder; tablet  
     filler; viscosity- increasing agent. 
 
Properties   
Loss on drying  : ≤ 3.0% 
Residue on ignition  : ≤ 4.0% 
Ethoxyl groups  : 44.0–51.0% 
Melting point   : 165
0
C to 180
0
 C 
Solubility   : Ethylcellulose is practically insoluble in glycerin,  
     propylene glycol, and water. Ethylcellulose that  
     contains less than 46.5% of ethoxyl groups is freely  
     soluble in chloroform, methyl acetate, and  
     tetrahydrofuran, and in mixtures of aromatic  
     hydrocarbons with ethanol (95%). 
Specific gravity  :  1.12–1.15 g/cm
3
 
Nominal viscosity  : 6–10 mPa s 
Stablility and storage  : Ethylcellulose is a stable, slightly hygroscopic material.  
     Ethylcellulose is subject to oxidative degradation in the  
     presence of sunlight or UV light at elevated  
     temperatures (Raymond C. Rowe et al., 2006). 
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DIBUTYL PTHALATE 
 
Synonyms   : Araldite 502; benzenedicarboxylic acid; benzene-o- 
     dicarboxylic acid di-n-butyl ester; butyl phthalate;  
     Celluflex DBP; Genoplast B; Hatcol DBP; Hexaplast  
     M/B. 
 
Nonproprietary names : BP: Dibutyl Phthalate  
PhEur: Dibutylis phthalas 
 
Chemical name   : Dibutyl benzene-1,2-dicarboxylate 
 
Empirical formula  : C16H22O4 
 
Molecular weight  : 278.34 
 
Structural formula   
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Description   : Dibutyl phthalate occurs as an odorless, oily, colorless,  
     or very slightly yellow-colored, viscous liquid. 
 
Functional categories  : Film-former; plasticizer; solvent. 
 
Properties   
Flash point   :  171
0
c 
Boiling point   : 340
0
c   
Refractive index  : 1.491 to 1.495   
Solubility   : very soluble in acetone, benzene, ethanol (95%), and  
     Ether; soluble 1 in 2500 of water at 200C. 
Relative density  : 1.043–1.048 
Dynamic viscosity  : 20 mPa s 
Stability and storage  : Dibutyl phthalate should be stored in a well-closed  
     container in a cool, dry, location. Containers may be  
     hazardous when empty since they can contain product  
     residues such as vapors and liquids  
     (Raymond C. Rowe et al., 2006). 
 
 
 
 
 
CHAPTER VIII                                                                                            EXCIPIENTS PROFILE 
PAGE 67 
 
DIMETHYL SULFOXIDE 
 
Synonyms   : Deltan; dimexide; dimethyl sulphoxide; DMSO; Kemsol; 
     Methylsulfoxide; Rimso-50; sulphinylbismethane  
     (Raymond C. Rowe et al., 2006). 
Nonproprietary names : BP: Dimethyl sulfoxide 
PhEur: Dimethylis sulfoxidum  
     USP: Dimethyl sulfoxide. 
 
Chemical name   : Sulfinylbismethane 
 
Empirical formula  : C2H6OS 
 
Molecular weight  : 78.13 
 
Structural formula   
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Description   : Dimethyl sulfoxide occurs as a colorless, viscous liquid,   
     that are miscible with water, alcohol, and ether, slightly  
     bitter taste with a sweet aftertaste and has a slight odor  
     characteristic of dimethyl sulfoxide. 
 
Functional categories  : Penetration enhancer; solvent. 
 
Properties   
Flash point   :  950c 
Boiling point   : 1890c   
Refractive index  : 1.478–1.479 (PhEur 2005)  
1.4755–1.4775 (USP 28)  
Solubility   : Miscible with water with evolution of heat; also miscible  
     with ethanol (95%), ether and most organic solvents; 
     immiscible with paraffins, hydrocarbons. Practically 
     insoluble in acetone, chloroform, ethanol (95%), and ether.  
Relative density  : 1.043–1.048 
Dynamic viscosity  : 1.1 mPa s (1.1 cP) at 27
0
C 
Stability and storage  : Dimethyl sulfoxide is reasonably stable to heat but upon 
prolonged reflux it decomposes slightly to methyl 
mercaptan and bismethylthiomethane. Dimethyl sulfoxide 
should be stored in airtight, light resistant containers. 
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POLYETHYLENE GLYCOL 
 
Synonyms   : Carbowax; Carbowax Sentry; Lipoxol; Lutrol E; PEG;  
     Pluriol E; polyoxyethylene glycol. 
 
Nonproprietary names : BP: Macrogols 
JP: Macrogol 400 
PhEur: Macrogola 
USPNF: Polyethylene glycol 
 
Chemical name   : a-Hydro-o-hydroxypoly (oxy-1,2-ethanediyl) 
 
Empirical formula  : HOCH2 (CH2OCH2) m CH2OH 
 
Molecular weight  : 380–420 
 
Structural formula   
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Description   : Liquid grades (PEG 200–600) occur as clear, colorless or 
slightly yellow-colored, viscous liquids. They have a slight   
but characteristic odor and a bitter, slightly burning taste. 
 
Functional categories  : Ointment base; plasticizer; solvent; suppository base; tablet  
     and capsule lubricant. 
 
Properties   
Flash point   :  238
0
c  
Refractive index  : 1.465  
Solubility   : Polyethylene glycols are soluble in acetone, alcohols,  
     benzene, glycerin, and glycols. 
Relative density  : 1.11–1.14 g/cm
3
 
Dynamic viscosity  : 105–130 mPa s 
Stability and storage  : Polyethylene glycols are chemically stable in air and in  
     solution. Polyethylene glycols should be stored in well 
     closed containers in a cool, dry place. Stainless steel,  
     aluminum, glass, or lined steel containers are preferred for  
     the storage of liquid grades. 
     (Raymond C. Rowe et al., 2006). 
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EXPERIMENTAL DETAILS 
A. PREPARATION OF STANDARD CALIBRATION CURVE 
Preparation of dissolution medium - phosphate buffered saline p
H
 7.4: 
Phosphate buffered saline pH is prepared by dissolving 2.38 g of disodium hydrogen 
phosphate, 0.19 g of potassium dihydrogen ortho phosphate and 8.0 g of sodium chloride in 
sufficient amount of water to produce 1000 ml (I.P 1996). 
Preparation of calibration curve for benazepril hydrochloride: 
For the preparation of calibration curve 100 mg benazepril hydrochloride is weighed and 
dissolved in a small quantity of Phosphate buffered saline pH 7.4 in a 100 ml standard flask and 
made up to the volume with Phosphate buffered saline pH 7.4. From this primary stock solution 
10 ml is pipetted out and made up to 100 ml with Phosphate buffered saline pH 7.4 to form the 
secondary stock solution resulting in the concentration of 100 µg/ml.  From the secondary stock 
solution 2ml, 4ml, 6ml, 8ml, 10ml, 12ml, 14ml 16ml, 18ml, 20ml samples are pipetted into 100 
ml volumetric standard flasks separately and made up to the volume with Phosphate buffered 
saline PH 7.4 to get concentrations of 2 µg/ml, 4 µg/ml,6 µg/ml,    8 µg/ml, 10 µg/ml, 12 µg/ml, 
14 µg/ml, 16 µg/ml, 18 µg/ml, 20 µg/ml of drug solutions respectively (Beata Stanisz et al., 
2009). 
λmax is found by scanning the benazepril hydrochloride solution under UV-Visible 
spectrophotometer. The absorbance is measured at λmax for different concentrated solutions to 
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obtain standard calibration curve. Standard calibration curve is plotted by taking concentration in 
x-axis and absorbance in y-axis. 
B. DRUG – POLYMER INTERACTION STUDIES  
This is carried out to check the compatibility between drug and various polymers. It is 
therefore necessary to confirm that drug is not interacting with polymers under experimental 
conditions and throughout the shelf life (Meenakshi Bharkatiya et al., 2010). The 
physicochemical compatibility between the drugs and polymers used in patches is studied by 
using FTIR and DSC studies. 
1) FTIR studies:  
Infra red spectroscopy is carried out on pure drug and physical mixtures of drug: polymer 
at 1:1 ratio is carried out between 500cm-1 – 5000cm-1 (Meenakshi Bharkatiya et al., 2010). 
2) Differential Scanning Calorimetry Study 
The physicochemical compatibility between the drugs and polymers used in patches is 
studied by using DSC studies. The DSC of the pure drug and physical mixtures of drug: polymer 
at 1:1 ratio is carried out. The sample is heated between 50ºC and 250º at the rate of 10ºC/min in 
an atmosphere of nitrogen (20 ml/min). The thermograms obtained for the drug, polymers, 
physical mixture of drugs with polymers are compared (Shyan Sundar Agrawal et al., 2011). 
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C. FORMULATION OF BENAZEPRIL HYDROCHLORIDE TRANSDERMAL 
PATCHES 
Matrix type transdermal patches containing benazepril hydrochloride are prepared by 
solvent casting technique employing a mercury substrate (Ashu Mitlal et al., 2009). Polymer 
solutions are prepared using ethanol as solvent (Rosilio V et al., 2009). To the polymeric 
solution known weight of drug (benazepril hydrochloride 69.3 mg) is added and mixed slowly 
with a glass rod for 20 minutes until a homogenous drug polymer solution is formed (Meenakshi 
Bharkatiya et al., 2010). Then plasticizer and permeation enhancer of required quantity are added 
and mixed thoroughly (Jianping Liu et al., 2009). The resulting homogenous drug-polymeric 
solution is poured on a mercury substrate (area of 13.86 cm2) in a petridish and dried at room 
temperature (Anilreddy B et al., 2010).The rate of evaporation of solvent is controlled by 
inverting a funnel over the petridish (Shashikant D. Barhate et al., 2009). The film formation is 
noted by observing the mercury surface after complete evaporation of the solvent (Meenakshi 
Bharkatiya et al., 2010). After drying at room temperature for 24 hours, membranes are taken 
out, packed in aluminium foil (Mamatha T., 2010) and stored in dessicator until further use 
(Anilreddy B et al., 2010). 
D. EVALUATION OF TRANSDERMAL PATCHES  
1) Physical appearance: 
All the transdermal patches are visually evaluated for their physical appearance 
opaque/transparent, smooth/wrinkled, flexible/tough, and sticky/nonsticky (Shyam Sudar 
Agarwal et al., 2011) 
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2) Weight variation: 
Weight variation is determined by weighing three patches individually, from each batch 
and the average weight, standard deviation are calculated for each formulation (Mamatha T           
et al., 2010). 
3) Thickness of the patch: 
The thicknesses of the transdermal patches are measured using a digital vernier caliper 
(Gilhotra Ritu Mehra et al., 2011). The measurements are made at three different places. The 
average and standard deviation of three readings are calculated for each formulation (Mamatha T 
et al., 2010). 
4) Folding endurance: 
Folding endurance is measured manually for the prepared patches.  It is expressed as 
number of times the patch is folded at the same place either to break the patch or to develop 
visible cracks. This is important to check the ability of sample to withstand folding. This also 
gives an indication of brittleness. For the determination of Folding endurance a strip of film            
(2 cm2) is cut evenly and repeatedly folded at the same place till it broken                          
(Aisha Khanum et al., 2008). The number of times the patch can be folded at the same place 
without breaking/cracking give the value of folding endurance. 
5) Flatness: 
The constriction of patches cut from a drug loaded matrix patch is an indicator of its 
flatness. Longitudinal strips are cut out from the prepared medicated patch, the lengths of each 
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strip are measured and then variation in the lengths due to non – uniformity in flatness is 
measured. Flatness is calculated by measuring construction of strips and a zero percent 
constriction is equivalent to a hundred percent flatness (Priyanka Arora et al., 2002). 
                             
Where, 
              L1 = Initial length of each strip, 
              L2 = Finial length of each strip. 
6) Percentage moisture content: 
The prepared films are weighed individually and kept in a desiccator containing silica gel 
at room temperature for 24 hours. The films are again weighed and the percentage moisture 
content is calculated using the formula (Mamatha T et al., 2010). 
 
 
7) Estimation of drug content: 
Transdermal patches of specified area (5 cm2) are cut into small pieces and are 
transferred into 50 ml standard flask. About 5 ml of ethanol is added to dissolve the patch and 
then made upto 50 ml with phosphate buffer saline pH 7.4. The solution is filtered, from the 
filtrate 5ml is transferred into 50 ml standard flask and made upto 50ml with phosphate buffer 
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saline pH 7.4. The absorbance of the solution is measured at 241.5 nm using UV visible 
spectrophotometer (Divyesh Patel et al., 2011).  
8) Invitro drug release studies:     
The in-vitro drug release study for the transdermal patches are carried out using modified 
paddle over disc assembly (USP Apparatus 5) (Martin Siewert et al., 2003). The disc apparatus 
(European Pharmacopoeia 5.0) consists of mesh screen made of stainless steel clamped in the 
watch glass using nylon clips. The transdermal patch of specified area is pasted over a small 
piece of aluminium foil (backing layer) to prevent two dimensional release. The transdermal 
patch with backing layer is placed between inert stainless steel mesh and watch glass exposing 
the patch to the medium. It is also ensured that the patch does not float inside the disc assembly. 
The disc assembly containing transdermal patch is placed at the bottom of the dissolution vessel, 
with the mesh facing upwards, under the rotating paddle. The dissolution medium used is 900 ml 
of Phosphate buffered saline pH 7.4 (Yogesh M. Amgaokar et al., 2011). The apparatus is 
equilibrated to the temperature of 32 ± 0.50c operated at 50 ± 1 rpm. The dissolution study is 
carried out for 12 hours. 5 ml of samples are withdrawn at regular intervals of 15 minutes for      
1 hour and then 30 minutes for next 11 hour. The same volume of corresponding dissolution 
medium is replenished to maintain sink condition. The amount of benazepril hydrochloride 
released is determined by measuring the absorbance of the samples at 241.5 nm using                       
UV-Visible spectrophotometer. Each test is performed in triplicate. 
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 9) Study of drug release kinetics 
In order to investigate the drug release mechanism from patches, the percentage                   
cumulative drug release data is analyzed with following mathematical model                           
(Yogesh M. Amgao Kar et al., 2011) 
Model Equation 
Zero order Kinetics Q = Q0 – K0t 
First order kinetics Q = Q0 ( 1 – e 
–K/t) 
Higuchi square root model Qt = KH t
1/2 
Korsmeyer-peppas model Qt / Q∞ = Kk t
n 
Hixson-Crowell cube root model 3√Q0 - 
3√Qt =KHC
t 
 
Where, 
Qt = Amount of drug released at time t 
Q0 = Initial amount of drug 
K0, K1, KH , KHC and KK are the coefficients of equation. The most appropriate model is 
selected on the basis of goodness of fit test. The zero order kinetic describes the systems in 
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which the drug release rate is independent of its concentration. The first order kinetics describes 
the system in which drug release rate is concentration dependent. Higuchi model describes the 
release of water – soluble drug from an insoluble matrix as a diffusion process based on the 
Fick’s law and is square root time dependent. The Hixson – Crowell cube root law describes the 
drug release from a system depends upon the change in surface area or diameter of particle or 
system and involves no diffusion mechanism. Korsmeyer – Peppas model describes the fraction 
of drug release relates exponentially with respect to time. This model is generally used to analyze 
the release of pharmaceutical polymeric dosage forms, when the release mechanism is not well 
known or when more than one type of release phenomena could be involved. 
10) Ex-vivo permeation studies: 
The ex vivo skin permeation experiments are conducted using vertical   type Franz 
diffusion cells having receptor compartment capacity of 15 ml (Naohiro Nishida et al., 2010).   
 Preparation of rat skin membrane  
Permeation studies are carried out after obtaining ethical committee clearance                         
(Ref. No. 14024/E1/4/2011). Wister strains of male albino rats weighing between 105-120 g                        
(Anilreddy B et al., 2010) are used for this study. Membrane for the permeability studies is full 
thickness skin from the abdominal region of the rats. The hair present over the skin is removed 
by trimming and careful shaving so that the skin is not damaged. The skin is excised from rat 
after anaesthetizing. The epidermis is prepared surgically by heat separation technique, which 
involved soaking the entire abdominal skin in water at 60ºC for 45 sec, followed by careful 
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removal of the epidermis (Madhusudan Rao Y et al., 2007). The excised skin samples are then 
stored in refrigerator at 0 - 4ºC and are used within three days (Yanli Gao et al., 2009). 
 Permeation studies 
The receptor compartment is filled with 15 ml of Phosphate buffered saline pH 7.4 
(Young – Charg Ah et al., 2010). The transdermal patches with backing membrane are firmly 
pressed onto the centre of the rat skin. Once adhesion to the skin surface had been confirmed, the 
skin is quickly mounted on the diffusion cell receptor compartment such that the patch is tightly 
secured over the flange aperture. The donor compartment is then placed in position and the two 
halves of the cell are clamped together. The whole assembly is placed over a magnetic stirrer. 
The dissolution medium in the receptor compartment is stirred constantly using a magnetic bead. 
The samples of 0.5 ml are withdrawn at regular time intervals of 1 hour and analyzed for drug 
content. Receptor phases are replenished with equal volume of fresh receptor medium at each 
time interval (Shengjie Bian et al., 2003). Each permeation experiment is repeated three times. 
The cumulative amounts of drug permeated and corrected for acceptor sample replacement is 
plotted against time (Alireza Ghaffari et al., 2007). 
 Determination of permeation parameters 
For the determination of permeation parameter, the cumulative amount of drug permeated 
across the skin is plotted against time. The steady state flux (J) is calculated from the slope of the 
linear region of the above plot. The lag time (T) is calculated by extrapolating the linear region 
of the curve to the X – axis (Srini N. Tenjarla et al., 1999). The permeability coefficient (Kp) is 
calculated from the ratio of flux to drug concentration in the donor chamber. 
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Kp = J/C  
Where, 
             Kp = Permeability coefficient 
               J   = Flux 
              C  = Initial drug load 
11) Statistical analysis 
Graph Pad In Stat Version 3.0 Software is used for statistical analysis. The cumulative 
amount permeated and flux values obtained are tested for the determination of significant 
differences using a one-way analysis of variance (ANOVA) (Venkateswara Rao J et al., 2010). 
12) Histopathology studies: 
Due to the possibility of changes to excised skin during extended in vitro experiments, 
Histopathological study is used to determine possible anatomical changes in rat skin. During the 
invitro experiments, a portion of skin (1 cm2) is collected from the proximal and distal dorsal 
side of each mouse. The proximal dorsal skin is marked A, and immediately stored in 10 % 
buffered formalin solution. The distal dorsal skin is marked B and kept in phosphate buffered 
saline pH 7.4 at 32º C  for a 12 hour period after which is stored in a 10 % buffered formalin 
solution. The skin portions in contact with transdermal patches and pure drug solution is 
removed from the Franz diffusion cells after the 12 hour experimental period and a cm2disc of 
skin cut from the centre of each skin portion. The skin portion in contact with transdermal patch 
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containing Eudragit L100 with DMSO is marked D, Eudragit L100 without DMSO is marked E, 
and in contact with pure drug solution is marked C. The marked skin portions are stored in 10 % 
buffered formalin solution. Sample A is used as control for normal living skin. Sample B act as a 
control to represent the in vitro experiment without the presence of benazepril hydrochloride                     
(in the form of pure drug or transdermal patch). The skin samples are embedded in paraffin and 
6µm sections are cut using a microtome. Hemotoxylin and eosin staining are performed                    
(Douw G. Muller et al., 2001).           
Morphological changes in the skin (especially in epidermal layers) after the permeation 
experiments are observed visually and classified on a scale of A – D (Gasem K.A.M. et al., 
2010).  
CLASS OBSERVATIONS INFERENCE 
A 
Morphology of the sample looks exactly similar 
to the control 
Nontoxic 
B Morphology looks almost similar to the control  Slightly toxic 
C 
Morphology includes partial epidermal 
degradation with nuclei bleeding in to the 
dermal layers 
Toxic 
D 
Morphology includes severe epidermal 
degradation with cell death 
Severely Toxic 
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E. SCANNING ELECTRON MICROSCOPY  
The external morphology of the transdermal patches is analyzed using scanning electron 
microscope. The samples placed on the stubs were coated finely with gold palladium alloy and 
examined under the microscope (Biswajit Mukherjee et al., 2005). 
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CHAPTER X 
RESULTS AND DISCUSSION 
A. PREPARATION OF STANDARD CALIBRATION CURVE 
Known concentration (10µg/ml) solution of benazepril hydrochloride in phosphate 
buffered saline pH 7.4 was scanned to find out the λmax and it was found to be 241.5 nm. The 
result was shown in Figure 1. The calibration curve for benazepril hydrochloride was prepared in 
phosphate buffered saline pH 7.4 in the concentration range of 2 to 20 µg/ml. The absorbances 
were measured at λmax of 241.5nm. The correlation coefficient was found to be 0.9996. The 
results were shown in Table 1 and Figure 2. 
B. DRUG – POLYMER INTERACTION STUDIES 
1) FTIR study 
 The IR Spectral analysis of benazepril hydrochloride alone showed that the principle 
peak were observed at wave number of 3504.43, 3111.28, 2978.18, 2805.01, 1735.99, 
1676.20,1643.41, 1317.43, 1200.20, 858.35, and 765.77 (cm
-1
) which indicates the presence of 
Carboxylic acid O-H stretch, Secondary amine N-H stretch, Methyl C-H stretch, Methylene C-H 
stretch, Carboxylic acid C=O stretch, Keto C=O stretch, Aromatic C=C ring stretch,          
RCOOR C-O stretch, R2NH C-N stretch, Tetra sub. aromatic C-H  stretch, and Mono sub 
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aromatic C-H stretch respectively. The results were shown in Figures3A, 3B, 3C, 3D, 3E, 3F & 
3G. In the IR spectra of the physical mixture of benazepril hydrochloride with ES100, EL100 & 
EC the principle peak were observed nearly at the same wave number as in benazepril 
hydrochloride pure drug. However some additional peaks were observed with physical mixture, 
which could be due to the presence of polymers. The result of FTIR study suggested that there is 
no interaction between the drug and polymers used in the present study (Madhusudan Rao Y et 
al., 2007). 
2) Differential Scanning Calorimetry Study 
 DSC study had been widely used as a rapid thermal method for examining the drug 
excipients compatibility because this method is fast, versatile and uses only mg of sample. When 
comparing the thermal behaviors of the pure drug, and the physical mixture of drug in polymer, 
analysis of the DSC curves can predict any interactions. In DSC thermogram the endothermic 
melting transition of benazepril hydrochloride was observed at 162.27 ºC. The results of DSC 
study were shown in Figure 4A, 4B, 4C, 4D, 4E, 4F, 4G & 4H. No shifts in the endothermic 
peak of Benazepril Hydrochloride or additional peaks were observed in the DSC thermogram of 
the physical mixture of Benazepril Hydrochloride and polymers (EC, ES100 & EL100) 
indicating  that no chemical interaction between Benazepril Hydrochloride and polymer occurred                          
(Liang Fang et al., 2007). 
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C. FORMULATION OF BENAZEPRIL HYDROCHLORIDE TRANSDERMAL                   
PATCHES 
Matrix type transdermal patches of benazepril hydrochloride were prepared by using 
polymers ethyl cellulose (EC), Eudragit S100 (ES100) and Eudragit L100 (EL100) in three 
different concentrations, (EC -2.5%, 3.0%, and 3.5% ; ES100 - 4.0%, 4.5%, and 5.0% ;               
EL100 - 4.5%, 5.0%, and 5.5%) with and without the addition of permeation enhancer                    
30% Dimethyl sulfoxide (DMSO). The patches were prepared by solvent casting technique using 
Polyethylene glycol 400 (PEG 400 5% for ES100, 2.5% for EL100) and Dibutyl phthalate (30% 
for EC) as a plasticizer (Gajanan Darwhekar et al., 2011). The compositions were shown in 
Table 2. 
D. EVALUATION OF TRANSDERMAL PATCHES 
1) Physical Appearance 
The use of mercury substrate method for the preparation of transdermal patches yielded 
opaque, smooth, flexible, nonsticky and uniform patches in case of ethylcellulose polymer where 
as  transparent, smooth, flexible, nonsticky and uniform patches in case of Eudragit polymer. The 
results were shown in Table 3. The results indicated that the method used for casting the film on 
a mercury substrate was found to be satisfactory. 
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2) Weight Variation 
The weight of the patches were ranged from 13.60 ± 0.4898 mg to 21.80 ± 0.2160 mg for 
ethylcellulose patches prepared with DMSO (F1, F3, and F5), 12.20 ± 0.4326 mg to                       
20.06 ± 0.7930 mg for ethylcellulose patches prepared without DMSO (F2, F4, and F6),                        
24.76 ± 0.4189 mg to 30.80 ± 0.5099 mg for Eudragit S100 patches prepared with DMSO                     
(F7, F9, and F11), 23.46 ± 0.6182 mg to 28.60 ± 1.4445 mg for Eudragit S100 patches prepared 
without DMSO (F8, F10, and F12), 11.70 ± 0.7118 mg to 26.03 ± 0.8178 mg for Eudragit L100 
patches prepared with DMSO (F13, F15, and F17), 11.30 ± 0.0471 mg to 24.90 ± 0.3741 mg for 
Eudragit L100 patches prepared without DMSO (F14, F16, and F18). The results were shown in 
Table 4 and Figure 5.  
From the results it was observed that the weight of the patches containing 
dimethylsulfoxide (F1, F3, F5, F7, F9, F11, F13, F15, and F17) was greater than that of patches 
prepared without permeation enhancer (F2, F4, F6, F8, F10, F12, F14, F16, and F18)                     
(Rupesh V. Chikhale et al., 2011). 
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3) Thickness of the patch 
The thickness of patches varied from 0.07 ± 0.005 mm to 0.31 ± 0.017 mm. The results 
were shown in Table 4 and in Figure 6. The thickness of the patches were found to increased in 
the following order, 
F1 - EC 2.5% with DMSO (0.08 ± 0.005 mm) < F3 - EC 3.0% with DMSO                    
(0.09 ± 0.005 mm) < F5 - EC 3.5% with DMSO (0.10 ± 0.011 mm) 
F2 - EC 2.5% without DMSO (0.07 ± 0.005 mm) < F4 - EC 3.0% without DMSO                       
(0.08 ± 0.005 mm) < F6 - EC 3.5% without DMSO (0.09 ± 0.010 mm) 
F7 - ES100 4.0% with DMSO (0.26 ± 0.005 mm) < F9 - ES100 4.5% with DMSO              
(0.27 ± 0.015 mm) < F11 - ES100 5.0% with DMSO (0.29 ± 0.005 mm) 
F8 - ES100 4.0% without DMSO (0.20 ± 0.010 mm) < F10 - ES100 4.5% without DMSO 
(0.23 ± 0.005 mm) < F12 - ES100 5% without DMSO (0.28 ± 0.011 mm) 
F13 - EL100 4.5% with DMSO (0.13 ± 0.011 mm) < F15 - EL100 5.0% with DMSO                          
(0.15 ± 0.005 mm) < F17 - EL100 5.5% with DMSO (0.18 ± 0.005 mm) 
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F14 - EL100 4.5% without DMSO (0.12 ± 0.015 mm) < F16 - EL100 5.0% without 
DMSO (0.14 ± 0.010 mm) < F18 - EL100 5.5% without DMSO (0.17 ± 0.017 mm) 
From the results it was observed that thickness of the patches increased with increase in 
concentration of polymer. The minimum standard deviation values assumed that the process used 
for preparing the patches was capable of giving reproducible results (Gajanan darwhekar et al., 
2011). 
4) Folding Endurance 
Folding endurance measures the ability of patch to withstand rupture. The results of 
folding endurance were shown in Table 4. The folding endurance of Eudragit patches                      
(F7 to F18) was ranged from 32.00 ± 0.6432 to 247.0 ± 1.6329 where as it was ranged from               
04.33 ± 0.4714 to 35.30 ± 1.2472 for the patches prepared with Ethylcellulose (F1 to F6).                 
From the results it was observed that the folding endurance was found to be high in patches 
containing Eudragit polymer when compared to the patches containing ethyl cellulose polymer 
(Meenakshi Bharkatiya et al., 2010). This was due to less film forming property of cellulose 
derivative when compared to Eudragit (Hemangi J. Patel et al., 2009) 
5) Flatness 
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All the formulations showed 100% flatness. The results of flatness study showed that 
none of the formulation had the difference in the strip lengths before and after longitudinal             
cut and thus they could maintain a smooth surface when applied on to the skin                           
(Gilhotra Ritu Mehra et al., 2011). 
6) Percentage Moisture Content 
The percentage moisture content in the patches was found to be low and ranged from 
1.52 ± 0.061 to 3.66 ± 0.43%.  The results were shown in Table 4 and Figure 7.  
The moisture content in the patches were found to be in the following order, 
F1 -EC 2.5% with DMSO (2.95 ± 0.086 %) > F3 -EC 3.0% with DMSO (1.86 ± 0.123 %) 
> F5 -EC 3.5% with DMSO (1.69 ± 0.173 %) 
F2 -EC 2.5% without DMSO (2.50 ± 0.061 %) > F4 -EC 3.0% without DMSO                
(2.15 ± 0.171 %) > F6 - EC 3.5% without DMSO (1.52 ± 0.061 %) 
F7 -ES100 4.0% with DMSO (3.66 ± 0.430 %) > F9 -ES100 4.5% with DMSO                     
(3.42 ± 0.291%) > F11 - ES100 5.0% with DMSO (2.23 ± 0.232 %) 
F8 -ES100 4.0% without DMSO (3.56 ± 0.318 %) > F10 -ES100 4.5% without DMSO                
(2.39 ± 0.158 %) > F12 -ES100 5% without DMSO (1.99 ± 0.323 %) 
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F13 -EL100 4.5% with DMSO (3.03 ± 0.174 %) > F15 -EL100 5.0% with DMSO                          
(2.52 ± 0.196 %) > F17 -EL100 5.5% with DMSO (2.34 ± 0.070 %) 
F14 -EL100 4.5% without DMSO (2.66 ± 0.039 %) > F16 -EL100 5.0% without DMSO          
(2.48 ± 0.399 %) > F18 -EL100 5.5% without DMSO (2.25 ± 0.037 %) 
 From the results it was observed that the moisture content decreases with increase 
in concentration of hydrophobic polymers in all the formulations. This could be due to increased 
hydrophobic nature of polymeric matrix which has less affinity for water which is resulted in 
decreased moisture content (Kevin C Garala et al., 2009). The moisture content in all the 
formulations helps them to remain stable and protect from being a completely dried and brittle 
film (Madhusudan Rao Y et al., 2007). 
7) Estimation of drug content 
The drug content of all the patches (F1 to F18) was in the range of 75.78 ± 0.63 to              
95.95 ± 1.09%. The results were shown in Table 4. The results suggest that the process employed 
to prepare the patches shown uniform drug content, with minimum batch variability                   
(Gajanan Darwhekar et al., 2011). 
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8) Invitro drug release studies 
The invitro drug release studies were performed using the modified paddle over disc 
apparatus (USP apparatus 5). The objective was to estimate, characterize and rationalize the drug 
release from matrix films (Gilhotra Ritu Mehra et al., 2011). The results of invitro drug release 
studies were shown in Tables 5, 6, 7, 8, 9, 10 and Figures 8A, 8B, 8C, 8D, 8E, 8F, 8G, 8H, 8I, 
8J, 8K, 8L, 8M, 8N & 8O. 
The cumulative percentage drug release of formulations containing Ethylcellulose            
(2.5%, 3.0%, and 3.5%) with DMSO in 12 hours were found to be 75.51% (F1), 60.55% (F3),                    
and 43.85% (F5). 
The cumulative percentage drug release of formulations containing Ethylcellulose            
(2.5%, 3.0%, and 3.5%) without DMSO in 12 hours were found to be 52.47% (F2), 44.68% (F4),                          
and 37.15% (F6). 
The cumulative percentage drug release of formulations containing Eudragit S100         
(4.0%, 4.5%, and 5.0%) with DMSO in 12 hours were found to be 81.26% (F7), 67.20% (F9),                 
and 63.48% (F11). 
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The cumulative percentage drug release of formulations containing Eudragit S100           
(4.0%, 4.5%, and 5.0%) without DMSO in 12 hours were found to be 71.97% (F8), 60.86% (F10),                          
and 49.76% (F12). 
The cumulative percentage drug release of formulations containing Eudragit L100         
(4.5%, 5.0%, and 5.5%) with DMSO in 12 hours were found to be 76.37% (F13), 64.75% (F15),                  
and 58.93% (F17). 
The cumulative percentage drug release of formulations containing Eudragit L100         
(4.5%, 5.0%, and 5.5%) without DMSO in 12 hours were found to be 65.83% (F14), 59.78% 
(F16), and 53.33% (F18). 
a) Effect of polymer on invitro drug release 
The cumulative percentage drug release of the formulations containing Eudragit L100              
(F13 - 76.37%, F14 - 65.83%, F15 - 64.75%, F16 - 59.78%, F17 - 58.93%, and F18 - 53.33%) and 
Eudragit S100 (F7 - 81.26%, F8 -71.97%, F9 - 67.20%, F10 - 60.86%, F11 - 63.48%, and                    
F12 - 49.76%) showed higher drug release when compared to the formulations containing 
Ethylcellulose (F1 - 75.51%, F2 - 52.47%, F3 - 60.55%, F4 - 44.68%, F5 - 43.85, and F6 - 37.15%). 
This was due to larger cavity size in Eudragit polymeric network and thus a faster mode of 
diffusion of drug from the Eudragit containing formulations as compared to the Ethylcellulose 
containing formulations (Biswajit Mukherjee et al., 2005). 
CHAPTER X                                                                                       RESULTS AND DISCUSSION 
PAGE 93 
 
b) Effect of polymer concentration on invitro drug release 
The cumulative percentage drug release of all the formulations decreased in the following 
order, 
F1 - EC 2.5% with DMSO (75.51%) > F3 - EC 3.0% with DMSO (60.55%) >                           
F5 - EC 3.5% with DMSO (43.85%) 
F2 - EC 2.5% without DMSO (52.47%) > F4 - EC 3.0% without DMSO (44.68) >                   
F6 - EC 3.5% without DMSO (37.15%) 
F7 - ES100 4.0% with DMSO (81.26%) > F9 - ES100 4.5% with DMSO (67.2%) >              
F11 - ES100 5.0% with DMSO (63.48%) 
F8 - ES100 4% without DMSO (71.97%) > F10 - ES100 4.5% without DMSO (60.86%) > 
F12 - ES100 5% without DMSO (49.76%) 
F13 - EL100 4.5% with DMSO (76.37%) > F15 - EL100 5% with DMSO (64.75%) >           
F17 - EL100 5.5% with DMSO (58.93%) 
F14 - EL100 4.5% without DMSO (65.83%) > F16 - EL100 5% without DMSO (59.78%) 
> F18 - EL100 5.5% without DMSO (53.33%) 
The cumulative percentage drug release of the  formulations containing EC – 2.5%, 
3.0%, and 3.5% (F1 to F6), ES100 – 4.0%, 4.5%, and 5.0% (F7 to F12) and EL100 – 4.0%, 5.0%, 
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and 5.5% (F13 to F18) were found to decrease with increase in concentration of EC, EL100, and 
ES100 in the formulations respectively (Kevin C Garala et al., 2009). This could be due to 
increased hydrophobic nature of polymeric matrix which has less affinity for water this resulted 
in decreased in thermodynamic activity of drug in the film and thus decreased drug release                          
(Gattani S.G. et al., 2007). 
c) Effect of plasticizer on invitro drug release 
The cumulative percentage drug release from Eudragit S100 formulations containing 
5.0% PEG 400 (F7 - 81.26%, F8 -71.97%, F9 - 67.20%, F10 - 60.86%, F11 - 63.48%, and                  
F12 - 49.76%)   were found to be greater than that of  Eudragit L100 formulations containing 
2.5% of Polyethylene glycol 400 (F13 - 76.37%, F14 - 65.83%, F15 - 64.75%, F16 - 59.78%,                
F17 - 58.93%, and F18 - 53.33%). This could be due to the addition of plasticizer change the 
physicochemical properties of the patches such as their polymer tortuosity and porosity which 
can influence drug diffusion (Fusun Acarturk et al., 1996). 
d) Effect of permeation Enhancer on invitro drug release 
 The cumulative percentage drug release from the formulations containing permeation 
enhancer (F1 - 75.51%, F3 - 60.55%, F5 - 43.85%, F7 - 81.26%, F9 - 67.20%, F11 - 63.48%,                
F13 - 76.37%, F15 - 64.75%, and F17 - 58.93%) was found to greater than that of the formulations 
prepared without permeation enhancer (F2 - 52.47%, F4 - 44.68%, F6 - 37.15%, F8 -71.97%,             
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F10 - 60.86%, F12 - 49.76%, F14 - 65.83%, F16 - 59.78%, and F18 - 53.33%). This could be due to 
miscibility and the solution properties of the permeation enhancer which were responsible for the 
enhanced drug release (Hemangi J. Patel et al., 2009). 
9) Study of drug release kinetics 
The description of dissolution profile by a model function has been attempted using 
different kinetics (zero order, first order, Higuchi square root model, Korsmeyer’s Peppas model 
and Hixson Crowell model) (M. Guyot et al., 2000). All the formulations (F1 – F18) showed zero 
order release kinetics (Fusan Acarturk et al., 1996). The correlation coefficient values (R2) were 
found to be in the range of 0.980 - 0.999. The results were shown in Table 12 and Figures 9A, 
9B, 9C, 9D, 9E, 9F, 9G, 9H, 9I, 9J, 9K, 9L, 9M, 9N & 9O. All the formulations were followed 
Higuchi mechanism. The correlation coefficient (R
2
) values were found to be in the range of 
0.977 – 0.998 (Hemangi J, Patel et al., 2009, P. Minghetti et al., 2000). The n values                
(0.5 < n < 1) of Korsmeyer’s peppas model indicated that the release of drug from all the patches 
followed anomalous transport (Ashu Mittal et al., 2009).  
10) Ex vivo permeability study 
 The formulation F17 (EL100 5.5% with DMSO) was selected for ex vivo permeability 
study on the basis of invitro release kinetics. For the determination of effect of permeation 
enhancer and polymer on ex vivo permeability formulation F18 (EL100 5.5% without DMSO) and 
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pure drug solution were selected for the ex vivo permeability study. The results of ex vivo drug 
permeation study were shown in Tables 11, 13 and 14, Figures 10A, 10B, 10C & 10D. 
The cumulative amount permeated from the formulation F17 (EL100 5.5% with DMSO) 
was found to be 0.9312 mg in 12 hours where as it was found to be 0.8079 mg for F18                
(EL100 5.5% without DMSO) and 1.1750 mg for pure drug solution. 
 The flux achieved during ex vivo permeation study were found to be 0.09228 mg/cm
2
/hr, 
0.05852 mg/cm
2
/hr and 0.05373 mg/cm
2
/hr for pure drug solution, formulation F17 (EL100 5.5% 
with DMSO) and F18 (EL100 5.5% without DMSO) respectively. 
 The lag time was found to be 1.0 hour for formulation F17 (EL100 5.5% with DMSO) 
where as it was found to be 1.1 hour for formulation F18 (EL100 5.5% without DMSO) and             
0.9 hour for pure drug solution. 
 The permeability coefficient was found to be 0.0169 h
-1
 for formulation F17 (EL100 5.5% 
with DMSO), 0.0111 h
-1
 for formulation F18 (EL100 5.5% without DMSO) and 0.0239 h
-1
 for 
pure drug solution. 
The result of drug permeation from transdermal patches of benazepril hydrochloride 
through the rat abdominal skin confirmed that benazepril hydrochloride was released from the 
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formulation and permeated through the skin and hence could possibly permeate through human 
skin (Madhusudan Rao Y et al., 2007). 
a) Effect of permeation enhancer on ex vivo permeability study 
 The formulation F17 exhibited the greatest cumulative amount of drug permeation 
(0.9312 mg) which was significantly high (P < 0.01) when compared to lowest                          
value (0.8079 mg) observed with the formulation F18 in 12 hours.  
 F17 - EL100 5.5% with DMSO (0.9312 mg) > F18 - EL100 5.5% without DMSO (0.8079 mg) 
The flux of formulation F17 (EL100 5.5% with DMSO) was found to be greater than that 
of formulation F18 (EL100 5.5% without DMSO). The flux were found to be the following order, 
F17 EL100 5.5% with DMSO (0.05852 mg/cm
2
/hr) > F18 EL100 5.5% without DMSO (0.05373 
mg/cm
2
/hr) 
The lag time of formulation F17 (EL100 5.5% with DMSO) was found to be less than that 
of formulation F18 (EL100 5.5% without DMSO). The lag time were found to be the following 
order, 
F17 EL100 5.5% with DMSO (1.0 hour) < F18 EL100 5.5% without DMSO (1.1hour) 
The above results indicated that the presence of dimethylsulfoxide in the formulation F17 
(EL100 5.5% with DMSO) increase the permeation of drug when compared to the formulation 
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F18 (EL100 5.5% without DMSO). Because dimethylsulfoxide being a powerful solvent can mix 
isothermally with water, it can displace water from the lipid head groups, creating gaps around 
these head group, it also capable of displacing water bound to protein head group. More over due 
to its solvent power high level of sulfoxide within the membrane can improve drug partitioning 
and thus increase the permeation. (Chandra Amrish et al., 2009). 
b) Effect of polymer on ex vivo permeability study 
The pure drug solution exhibited the greatest cumulative amount of drug permeation              
and flux which were significantly high (P < 0.001) when compared to the lowest value observed 
with the formulations (F17 and F18). 
 The cumulative amount of drug permeation were found to be the following order, 
Pure drug solution (1.1750 mg) > F17 - EL100 5.5% with DMSO (0.9312 mg) > F18 - EL100 
5.5% without DMSO (0.8079 mg) 
The flux were found to be the following order, 
Pure drug solution (0.09228 mg/cm
2
/hr) > F17 EL100 5.5% with DMSO (0.05852 mg/cm
2
/hr)               
> F18 EL100 5.5% without DMSO (0.05373 mg/cm
2
/hr) 
The decline in permeation observed with the film when compared to the pure drug 
solution could be due to drug depletion in the region of the film in contact with the skin. The 
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results obtained with the ex vivo permeability study suggest that the element of control of drug 
permeation across skin was the release of the drug from the formulation (Patrizia santi et. al., 
2007). 
c) Release kinetics of ex vivo permeability  
 The description of permeation profile by a model function has been attempted 
using different kinetics (zero order, first order, Higuchi square root model, Korsmeyer’s peppas 
model and Hixson Crowell model) (M. Guyot et al., 2000). The results were shown in Table 15 
and Figures 11A, 11B, 11C, 11D & 11E. 
Formulations F17 and F18 showed zero order release kinetics (Fusan Acarturk et al., 
1996). The correlation coefficient values (R
2
) were found to be 0.975 and 0.990. The 
formulations F17 and F18 were followed Higuchi mechanism. The correlation coefficient (R
2
) 
values were found to be 0.955 and 0.979. The n values of Korsmeyer’s peppas model indicated 
that the release of drug from the formulations F17 (n = 0.524) followed Fickian diffusion 
mechanism (Jatin Kumar Pruthi et al., 2011) where as formulation F18 (n = 0.604) followed 
anomalous transport (Ashu Mittal et al., 2009).   
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d) Dose design 
 Theoretical drug input required was calculated using the following mathematical 
equation, (Ashu Mittal et al., 2009) 
 Drug input (theoretical) = Css × Ke × Vd 
          = 138 µg/hr 
The flux achieved after ex vivo permeability study of 1cm
2
 of patch was found to be 
0.05852 mg/cm
2
/hr. Hence by increasing the surface area of the formulation to 2.36 cm
2 
the 
required rate of flux may be achieved. 
11) Histopathological study 
 The results of histopathological studies were shown in Table 16 and Figures 12A, 12B, 
12C, 12D & 12E. 
 The sample A (normal healthy rat abdominal skin) showed intact stratum corneum with 
muscle bundle and fat. The result indicated that there is no histological abnormalities could 
found in the skin section of the control group (A). 
 The sample B (rat abdominal skin in contact with phosphate buffered saline pH 7.4 for         
12 hours) showed fibro fatty tissue, inflammatory cell infiltrate and oedema. Identical changes 
were presented in the samples from group C (rat abdominal skin in contact with benazepril 
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hydrochloride pure drug solution for 12 hours), group D (rat abdominal skin in contact with F17 
formulation containing EL100 5.5% with DMSO), group E (skin in contact with F18 formulation 
containing EL100 5.5% without DMSO). The results indicated that there is no anatomical 
degradation which was observed in the morphology of skin sample exposed to formulation     
(F17, F18) and pure drug solution. (Gasem K.A.M. et al., 2010). Hence the enhanced permeation 
of formulation containing dimethylsulfoxide could be due to its solvent action which resulted in 
increased drug partition in to the skin (pooja Mathur et al., 2011). 
E. SCANNING ELECTRON MICROSCOPY 
 The surface morphology of the transdermal patch before and after invitro drug release 
study was scanned using a scanning electron microscope. The results were shown in Figures 13A 
& 13B. 
 Figure 13A showed surface morphology of the patch before ex vivo permeation study 
which indicated that the uniform distribution of drug in the polymer matrix. 
 Figure 13B showed surface morphology of the patch after ex vivo permeation study. 
From the result it was observed that the film maintained the elastic nature after the release of 
drug molecule without affecting the other parts of the patch (Priyanka Arora et al., 2002). 
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CHAPTER XI 
SUMMARY AND CONCLUSION 
In the present work an attempt has been made to formulate and evaluate the transdermal 
patches of benazepril hydrochloride using various types of polymers (Eudragit L100,              
Eudragit S100 and ethylcellulose). 
The results of compatibility studies by Fourier transform infrared spectroscopy and 
differential scanning Calorimetry showed no interaction between the drug and polymers. 
The polymers Eudragit L100 and Eudragit S100 used for the formulation of transdermal 
patches showed good film forming property when compared to ethylcellulose. 
The patches prepared by using Eudragit L100 and Eudragit S100 were thin, flexible, 
smooth and transparent where as the patches prepared by using ethylcellulose were thin, flexible, 
smooth and opaque. 
The weight variation test showed less variation in weight and suggesting uniform 
distribution of drug and polymer over the mercury surface. 
The thickness of the transdermal patches increased with increasing the concentration of 
polymers Eudragit L100, Eudragit S100 and ethylcellulose. 
Eudragit patches showed good flexibility and folding endurance properties when 
compared to ethylcellulose patches. 
All the formulations showed 100% flatness which indicating that all patches could 
maintain a smooth surface when applied on to the skin. 
The moisture content in the patches were found to low and the formulations containing 
high concentrations of hydrophobic polymer showed low percentage of moisture content. 
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The drug content analysis showed minimum variations suggesting uniform distribution of 
drug. 
In vitro release studies suggested that drug release of all the formulations decreased  with 
increase in polymer concentration.  
The kinetic analysis of in vitro drug release studies suggested that all the formulations 
followed zero order release kinetics and non Fickian diffusion mechanism.  
The results of ex vivo permeation studies showed that the addition of dimethyl sulfoxide 
increased the permeation of drug and the required target flux can be achieved by increasing 
surface area of the patch to 2.36 cm
2
.     
The results of histopathological study suggested that the addition of permeation enhancer 
increased the permeation of drug through the skin by means of its solvent action and thus it did 
not cause anatomical degradation in the skin.  
Surface morphological studies by scanning electron microscopy showed that the patch 
showed uniform smooth surface and did not lose integrity after release. 
Hence it was concluded that solvent casting method using mercury substrate was useful 
for successful development of matrix type transdermal patches of benazepril hydrochloride. The 
controlled release of drug from the transdermal patches suggested that the frequency of 
administration can be reduced. The transdermal patches can improve the bioavailability of the 
benazepril hydrochloride by avoiding hepatic first pass metabolism. Further in vivo investigation 
was required to correlate ex vivo permeation studies for the development of suitable transdermal 
system of benazepril hydrochloride. The present investigation suggested that the matrix type 
transdermal patches of benazepril hydrochloride could be explored for the management of 
hypertension. 
Table 1 
CALIBRATION CURVE OF BENAZEPRIL HYDROCHLORIDE USING PHOSPHATE 
BUFFERED SALINE PH 7.4 
Sl.no Concentration µg/ml Absorbance ± S.D
* 
1 2 0.043 ± 0.0000 
2 4 0.083 ± 0.0016 
3 6 0.128 ± 0.0049 
4 8 0.163 ±0.0016 
5 10 0.198 ± 0.0008 
6 12 0.247 ± 0.0058 
7 14 0.285 ± 0.0049 
8 16 0.333 ± 0.0060 
9 18 0.371 ± 0.0071 
10 20 0.414 ± 0.0104 
γ = 0.9996 
*
n = 3 
 
 
 
 
 
 
 
Table 2 
COMPOSITION OF TRANSDERMAL PATCHES OF BENAZEPRIL 
HYDROCHLORIDE 
 
Sl.no 
 
Formulation 
Code 
 
Polymer 
 
Weight  
(mg) 
 
Dibutyl 
phthalate  
(% w/w of  
polymer) 
 
Poly ethylene        
glycol            
(% w/w of  
polymers) 
 
Dimethyl 
sulfoxide    
(% w/w of  
polymer ) 
1 F1 EC 125 30 _ 30 
2 F2 EC 125 30 _ _ 
3 F3 EC 150 30 _ 30 
4 F4 EC 150 30 _ _ 
5 F5 EC 175 30 _ 30 
6 F6 EC 175 30 _ _ 
7 F7 ES100 200 _ 5 30 
8 F8 ES100 200 _ 5 _ 
9 F9 ES100 225 _ 5 30 
10 F10 ES100 225 _ 5 _ 
11 F11 ES100 250 _ 5 30 
12 F12 ES100 250 _ 5 _ 
13 F13 EL100 225 _ 2.5 30 
14 F14 EL100 225 _ 2.5 _ 
15 F15 EL100 250 _ 2.5 30 
16 F16 EL100 250 _ 2.5 _ 
17 F17 EL100 275 _ 2.5 30 
18 F18 EL100 275 _ 2.5 _ 
Table 3 
S.NO FORMULATION CODE PHYSICAL APPEARANCE 
1 F1-EC 2.5% (with DMSO)  opaque, smooth, nonsticky and flexible 
2 F2- EC 2.5% (without DMSO) opaque, smooth, nonsticky and flexible 
3 F3- EC 3.0% (with DMSO) opaque, smooth, nonsticky and flexible 
4 F4- EC 3.0% (without DMSO) opaque, smooth, nonsticky and flexible 
5 F5- EC 3.5% (with DMSO) opaque, smooth, nonsticky and flexible 
6 F6- EC 3.5% (without DMSO) opaque, smooth, nonsticky and flexible 
7 F7- ES100 4.0% (with DMSO) Transparent, smooth, nonsticky and flexible 
8 F8- ES100 4.0% (without DMSO) Transparent, smooth, nonsticky and flexible 
9 F9- ES100 4.5% (with DMSO) Transparent, smooth, nonsticky and flexible 
10 F10- ES100 4.5%(without DMSO) Transparent, smooth, nonsticky and flexible 
11 F11- ES100 5.0% (with DMSO) Transparent, smooth, nonsticky and flexible 
12 F12- ES100 5.0%(without DMSO) Transparent, smooth, nonsticky and flexible 
13 F13- EL100 4.5% (with DMSO) Transparent, smooth, nonsticky and flexible 
14 F14- EL100 4.5%(without DMSO) Transparent, smooth, nonsticky and flexible 
15 F15- EL100 5.0% (with DMSO) Transparent, smooth, nonsticky and flexible 
16 F16- EL100 5.0%(without DMSO) Transparent, smooth, nonsticky and flexible 
17 F17- EL100 5.5% (with DMSO) Transparent, smooth, nonsticky and flexible 
18 F18- EL100 5.5%(without DMSO) Transparent, smooth, nonsticky and flexible 
 
Table 4 CHARACTERISATION OF BENAZEPRIL HYDROCHLORIDE                   
TRANSDERMAL PATCHES 
Formulation 
Code 
 
Weight ± S.D
*
 
(mg) 
 
Thickness ± 
S.D
*
(mm) 
Folding 
Endurance ± 
S.D
*
 (No. of 
times) 
Moisture 
content ± 
S.D
*
 (%) 
Drug 
content ± 
S.D
* 
(%) 
F1 13.60 ± 0.4898 0.08 ± 0.005 09.33 ± 0.4714 2.95 ± 0.086 84.00 ± 2.52 
F2 12.20 ± 0.4326 0.07 ± 0.005 04.33 ± 0.4714 2.50 ± 0.061 85.83 ± 1.01 
F3 18.06 ± 1.2656 0.09 ± 0.005 06.66 ± 0.4714 1.86 ± 0.123 89.38 ± 2.29 
F4 15.70 ± 0.5099 0.08 ± 0.005 05.66 ± 0.4714 2.15 ± 0.171 84.67 ± 2.89 
F5 21.80 ± 0.2160 0.10 ± 0.011 35.30 ± 1.2472 1.69 ± 0.173 75.78 ± 0.63 
F6 20.06 ± 0.7930 0.09 ± 0.010 07.33 ± 0.4714 1.52 ± 0.061 87.36 ± 1.24 
F7 24.76 ± 0.4189 0.26 ± 0.005 46.00 ± 0.8164 3.66 ± 0.430 92.08 ± 0.86 
F8 23.46 ± 0.6182 0.20 ± 0.010 32.00 ± 0.6432 3.56 ± 0.318 81.98 ± 1.86 
F9 29.40 ± 0.6539 0.27 ± 0.015 189.3 ± 1.2472 3.42 ± 0.291 91.40 ± 1.24 
F10 26.23 ± 0.3299 0.23 ± 0.005 145.0 ± 3.9665 2.39 ± 0.158 84.50 ± 1.86 
F11 30.80 ± 0.5099 0.29 ± 0.005 152.6 ± 2.0548 2.23 ± 0.232 82.48 ± 3.33 
F12 28.60 ± 1.4445 0.28 ± 0.011 149.5 ± 2.3342 1.99 ± 0.323 87.36 ± 0.71 
F13 11.70 ± 0.7118 0.13 ± 0.011 247.0 ± 1.6329 3.03 ± 0.174 83.32 ± 2.29  
F14 11.30 ± 0.0471 0.12 ± 0.015 197.0 ± 0.8164 2.66 ± 0.039 87.32 ± 0.63 
F15 25.53 ± 1.0498 0.15 ± 0.005 221.0 ± 1.6329 2.52 ± 0.196 95.95 ± 1.09 
F16 22.13 ± 2.6599 0.14 ± 0.010 171.7 ± 0.9428 2.48 ± 0.399 85.68 ± 1.26 
F17 26.03 ± 0.8178 0.18 ± 0.005 129.3 ± 0.4714 2.34 ± 0.070 77.77 ± 1.24 
F18 24.90 ± 0.3741 0.17 ± 0.017 105.7 ± 1.2472 2.25 ± 0.037 86.52 ± 1.04 
*
n = 3 
Table 5 
IN VITRO RELEASE PROFILE OF BENAZEPRIL HYDROCHLORIDE 
TRANSDERMAL PATCH 
 
Time 
(Hours) 
Cumulative % Drug Release 
Formulation Code 
F1 EC 2.5%                
(with DMSO) 
F2 EC 2.5%                
(without DMSO) 
F3 EC 3.0%                
(with DMSO) 
Mean ± SD
*
(%) Mean ± SD
*
(%) Mean ± SD
* 
(%) 
0.25 13.92 ± 2.47 10.08 ±2.22 10.42 ±2.09 
0.50 15.92 ±2.13 12.29 ±2.71 13.04 ±1.20 
0.75 18.52 ±2.42 13.04 ±2.97 14.29 ±1.69 
1.00 20.43 ±2.09 13.85 ±3.03 15.93 ±0.77 
1.50 22.49 ±1.47 17.92 ±3.02 17.70 ±1.39 
2.00 25.61 ±1.90 19.57 ±1.56 19.11 ±0.55 
2.50 28.51 ±3.18 22.80 ±1.56 20.53 ±0.21 
3.00 32.50 ±1.11 24.48 ±1.90 22.21 ±0.55 
3.50 35.32 ±1.09 26.18 ±1.25 24.13 ±0.60 
4.00 41.02 ±2.87 28.48 ±1.79 25.82 ±0.32 
4.50 44.49 ±2.24 29.83 ±2.16 28.36 ±1.01 
5.00 46.16 ±1.98 30.35 ±1.67 31.22 ±1.58 
5.50 47.97 ±1.14 31.79 ±2.56 32.99 ±2.09 
6.00 49.91 ±1.02 34.40 ±2.00 34.49 ±2.21 
6.50 52.82 ±2.60 35.19 ±2.55 35.99 ±2.67 
7.00 54.41 ±1.89 38.61 ±3.08 38.46 ±2.59 
7.50 58.07 ±2.52 39.9 ±2.66 40.46 ±1.52 
8.00 60.89 ±2.54 41.07 ±2.81 41.92 ±1.62 
8.50 63.25 ±2.49 42.36 ±2.42 44.42 ±1.25 
9.00 65.86 ±2.19 43.42 ±2.72 46.47 ±1.28 
9.50 68.00 ±2.21 46.05 ±1.25 47.42 ±1.25 
10.0 69.69 ±1.06 47.49 ±1.69 51.26 ±1.27 
10.5 71.73 ±1.20 48.81 ±2.20 53.60 ±1.50 
11.0 73.19 ±0.86 50.26 ±1.35 55.53 ±1.47 
11.5 74.52 ±1.19 51.61 ±1.73 58.46 ±2.24 
12.0 75.51 ±1.08 52.47 ±1.21 60.55 ±1.01 
*
n = 3 
 
Table 6 
IN VITRO RELEASE PROFILE OF BENAZEPRIL HYDROCHLORIDE 
TRANSDERMAL PATCH 
 
Time 
(Hours) 
Cumulative % Drug Release 
Formulation Code 
F4 EC 3.0%                 
(without DMSO) 
F5 EC 3.5%                
(with DMSO) 
F6 EC 3.5%                
(without DMSO) 
Mean ± SD
*
(%) Mean ± SD
*
(%) Mean ± SD
*
(%) 
0.25 07.80 ± 1.61 05.79 ±2.28 03.99 ± 1.52 
0.50 09.62 ± 1.49 09.10±2.20 05.19 ± 2.00 
0.75 11.02 ± 1.78 12.60 ± 3.27 06.41 ± 1.49 
1.00 13.00 ± 1.41 14.99 ± 4.78 09.8 0± 1.48 
1.50 14.75 ± 1.21 15.82 ± 2.74 11.29 ± 1.08 
2.00 16.27 ± 0.87 17.48 ± 3.33 12.56 ± 1.19 
2.50 17.56 ± 0.97 18.42 ± 2.61 13.35 ± 0.74 
3.00 19.33 ± 0.37 17.51 ± 4.34 15.10 ± 1.50 
3.50 20.99 ± 0.30 22.23 ± 2.46 16.99 ± 1.50 
4.00 22.31 ± 0.47 23.43 ± 2.19 18.64 ± 1.55 
4.50 23.63 ± 1.32 24.52 ± 2.94 19.58 ± 1.44 
5.00 24.84 ± 1.17 27.05 ± 1.93 20.52 ± 1.61 
5.50 26.05 ± 1.74 28.18 ± 1.57 21.83 ± 2.06 
6.00 28.23 ± 1.45 30.16 ± 2.76 23.03 ± 2.30 
6.50 30.30 ± 1.45 30.92 ± 3.75 24.35 ± 2.75 
7.00 31.66 ± 2.23 32.92 ± 3.33 25.20 ± 1.88 
7.50 33.51 ± 2.69 34.14 ± 3.43 27.25 ± 2.23 
8.00 35.12 ± 3.20 34.92 ± 3.70 28.6 0± 2.12 
8.50 36.15 ± 3.18 35.34 ± 4.71 29.83± 1.82 
9.00 37.78 ± 2.55 37.93 ± 5.33 31.16 ± 1.86 
9.50 39.06 ± 2.64 38.72 ± 4.95 33.03 ± 1.66 
10.0 39.98 ± 2.44 39.64 ± 5.47 33.56 ± 1.44 
10.5 41.03 ± 2.44 40.92 ± 6.07 33.50 ± 1.26 
11.0 42.68 ± 2.15 41.86 ± 6.11 34.51 ± 1.62 
11.5 43.86 ± 1.63 43.03 ± 6.30 36.13 ± 1.98 
12.0 44.68 ± 2.03 43.85 ± 6.14 37.15 ± 2.13 
*
n = 3 
 
 
Table 7 
 IN VITRO RELEASE PROFILE OF BENAZEPRIL HYDROCHLORIDE 
TRANSDERMAL PATCH 
 
Time 
(Hours) 
Cumulative % Drug Release 
Formulation Code 
F7 ES100 4.0%             
(with DMSO) 
F8 ES100 4.0%             
(without DMSO) 
F9 ES100 4.5%             
(with DMSO) 
Mean ± SD
*
(%) Mean ± SD
*
(%) Mean ± SD
*
(%) 
0.25 17.52±1.89 10.32 ± 0.85 08.52 ± 2.24 
0.50 25.17±2.66 16.13 ± 0.34 10.24 ± 2.40 
0.75 26.99 ± 2.21 18.75 ± 1.52 11.38 ± 1.91 
1.00 28.71 ± 2.92 20.05 ± 0.52 13.49 ± 2.07 
1.50 31.62 ± 4.59 21.96 ± 1.56 15.48 ± 2.29 
2.00 32.88 ± 4.62 24.48 ± 0.35 17.73 ± 3.23 
2.50 34.98 ± 3.81 25.93 ± 0.76 19.38 ± 3.14 
3.00 36.97 ± 4.02 27.87 ± 0.76 21.49 ± 2.25 
3.50 40.29 ± 2.50 29.22 ± 1.20 24.28 ± 2.90 
4.00 42.30 ± 2.49 31.18 ± 1.78 27.65 ± 2.62 
4.50 45.17 ± 3.15 33.39 ± 1.82 30.08 ± 1.68 
5.00 48.29 ± 4.34 35.85 ± 1.55 32.89 ± 2.39 
5.50 50.11 ± 5.10 38.56 ± 0.74 35.71 ± 3.37 
6.00 51.21 ± 5.11 40.80 ± 1.56 37.57 ± 2.82 
6.50 54.12 ± 5.37 41.98 ± 1.12 39.47 ± 3.57 
7.00 58.00 ± 7.72 44.48 ± 0.92 42.67 ± 3.39 
7.50 60.60 ± 7.28 47.84 ± 1.50 46.49 ± 4.43 
8.00 62.83 ± 7.26 51.09 ± 0.80 48.06 ± 4.82 
8.50 64.84 ± 7.85 53.28 ± 0.90 52.63 ± 3.64 
9.00 67.93 ± 7.20 58.12 ± 0.74 55.67 ± 1.77 
9.50 69.73 ± 7.49 59.87 ± 1.75 58.25 ± 0.84 
10.0 73.05 ± 6.03 62.22 ± 2.02 60.35 ± 1.74 
10.5 75.39 ± 5.92 64.58 ± 3.83 63.79 ± 2.34 
11.0 77.81 ± 5.28 66.00 ± 2.18 64.48 ± 2.84 
11.5 79.89 ± 4.60 69.09 ± 0.97 66.85 ± 2.26 
12.0 81.26 ± 3.58 71.97 ± 0.77 67.20 ± 3.36 
*
n = 3 
Table 8 
IN VITRO RELEASE PROFILE OF BENAZEPRIL HYDROCHLORIDE 
TRANSDERMAL PATCH 
 
Time 
(Hours) 
Cumulative % Drug Release 
Formulation Code 
F10 ES100 4.5%            
(without DMSO) 
F11 ES100 5.0%            
(with DMSO) 
F12 ES100 5.0%             
(without DMSO) 
Mean ± SD
*
(%) Mean ± SD
*
(%) Mean ± SD
*
(%) 
0.25 07.92 ± 1.47 06.24 ± 2.25 05.52 ± 1.03 
0.50 10.00 ± 1.51 08.20 ± 2.97 07.25 ± 1.05 
0.75 11.74 ± 1.03 10.04 ± 1.80 10.63 ± 1.37 
1.00 14.08 ± 1.18 11.54 ± 1.92 12.13 ± 0.69 
1.50 15.12 ± 2.38 12.44 ± 3.32 13.16 ± 1.49 
2.00 18.08 ± 3.41  14.19 ± 3.37 14.79 ± 1.21 
2.50 19.66 ± 3.24 15.18 ± 3.84 17.27 ± 1.58 
3.00 20.45 ± 3.36 17.34 ± 5.05 19.64 ± 1.92 
3.50 22.84 ± 3.90 19.12 ± 6.19  21.67 ± 2.61 
4.00 24.40 ± 3.81 21.62 ± 6.62 03.31 ± 2.98 
4.50 26.09 ± 3.50 23.78 ± 5.59 24.67 ± 2.89 
5.00 29.12 ± 3.66 24.51 ± 6.56 26.01 ± 2.58 
5.50 32.03 ± 4.86 26.08 ± 6.82 28.18 ± 2.88 
6.00 34.60 ± 5.69 28.02 ± 6.86 29.05 ± 2.66 
6.50 38.03 ± 5.96 30.33 ± 5.76 30.77 ± 2.36 
7.00 39.67 ± 6.27 32.53 ± 6.13 33.09 ± 3.28 
7.50 41.32 ± 4.51 34.98 ± 5.31 34.59 ± 3.34 
8.00 45.26 ± 5.07 37.09 ± 4.00 36.81 ± 3.19 
8.50 46.46 ± 5.05 40.64 ± 3.47 39.17 ± 3.01 
9.00 48.74 ± 5.43 43.86 ± 4.09 40.21 ± 3.19 
9.50 50.44 ± 5.31 47.33 ± 3.06 41.74 ± 3.24 
10.0 52.17 ± 4.78 49.50 ± 2.53 43.40 ± 3.57 
10.5 54.46 ± 3.33 51.32 ± 2.73 45.19 ± 3.29 
11.0 56.54 ± 3.31 56.03 ± 1.66 46.94 ± 3.44 
11.5 59.35 ± 0.78 60.28 ± 1.22 48.78 ± 1.79 
12.0 60.86 ± 1.36 63.48 ± 2.28 49.76 ± 1.83 
 
*
n = 3 
 
 
Table 9 
IN VITRO RELEASE PROFILE OF BENAZEPRIL HYDROCHLORIDE 
TRANSDERMAL PATCH 
 
Time 
(Hours) 
Cumulative % Drug Release 
Formulation Code 
F13 EL100 4.5%            
(with DMSO) 
F14 EL100 4.5%            
(without DMSO) 
F15 EL100 5.0%            
(with DMSO) 
Mean ± SD
*
(%) Mean ± SD
*
(%) Mean ± SD
*
(%) 
0.25 09.36 ± 1.56 07.20 ± 1.06 07.56 ± 1.06 
0.50 12.05 ± 2.74 09.04 ± 1.07 09.40 ± 0.52 
0.75 13.92 ± 3.25 10.53 ± 1.48 11.25 ± 1.07 
1.00 16.16 ± 3.54 11.55 ± 1.34 12.39 ± 0.60 
1.50 17.80 ± 3.36 13.24 ± 2.30 13.78 ± 0.86 
2.00 19.70 ± 3.25 15.40 ± 2.55 16.62 ± 0.36 
2.50 21.73 ± 3.67 17.29 ± 2.17 19.23 ± 0.33 
3.00 23.65 ± 3.01 19.66 ± 2.27 21.85 ± 0.84 
3.50 26.17 ± 3.30 22.41 ± 1.96 24.26 ± 1.18 
4.00 27.64 ± 3.43 25.29 ± 2.65 27.02 ± 1.83 
4.50 29.22 ± 3.23 27.74 ± 2.92 29.09 ± 2.25 
5.00 30.82 ± 2.75 30.41 ± 3.37 31.29 ± 2.53 
5.50 33.74 ± 2.74 32.37 ± 2.95 33.73 ± 3.27 
6.00 35.84 ±1.91 33.99 ± 2.50 36.56 ± 3.96 
6.50 38.80 ± 1.27 37.70 ±  3.31 39.15 ± 3.79 
7.00 41.76 ± 1.80 40.49 ± 3.42  41.76 ± 4.20 
7.50 45.47 ± 1.95 42.98 ± 3.72 43.42 ± 4.07 
8.00 48.58 ± 2.79 45.02 ± 4.11 45.67 ± 5.02 
8.50 50.76 ± 3.42 47.05 ± 4.13 47.97 ± 6.37 
9.00 52.83 ± 2.64 48.90 ± 4.52 50.87 ± 6.64 
9.50 55.03 ± 2.61 51.04 ± 4.53 52.57 ± 6.34 
10.0 59.15 ± 2.96 54.19 ± 4.32 55.14 ± 5.08 
10.5 61.74 ± 2.64 56.27 ± 3.54 57.82 ± 4.88 
11.0 65.07 ± 3.05 59.80 ± 2.92  59.56 ± 3.38 
11.5 69.12 ± 2.51 62.99 ± 2.56 62.26 ± 3.00 
12.0 76.37 ± 2.10 65.83 ± 1.04 64.75 ± 0.93 
  
*
n = 3 
Table 10 
IN VITRO RELEASE PROFILE OF BENAZEPRIL HYDROCHLORIDE 
TRANSDERMAL PATCH 
 
Time 
(Hours) 
Cumulative % Drug Release 
Formulation Code 
F16 EL100 5.0%             
(without DMSO) 
F17 EL100 5.5%             
(with DMSO) 
F18 EL100 5.5%             
(without DMSO) 
Mean ± SD
*
(%) Mean ± SD
*
(%) Mean ± SD
*
(%) 
0.25 06.12 ± 1.47 08.16 ± 0.34 08.4 ± 1.77 
0.50 07.83 ± 1.37 10.00 ± 1.19 09.41 ± 1.94 
0.75 10.16 ± 1.08 11.14 ± 0.85 11.14 ± 1.82 
1.00 11.53 ± 1.34 13.24 ± 1.34 12.88 ± 1.80 
1.50 13.28 ± 1.35 14.75 ± 1.21 14.63 ± 2.07 
2.00 15.39 ± 1.58 16.88 ± 1.49 16.03 ± 2.24 
2.50 17.17 ± 1.73 18.53 ± 1.54 18.16 ± 2.30 
3.00 20.01 ± 1.42 20.07 ± 1.73 19.70 ± 2.26 
3.50 21.55 ± 1.40 21.98 ± 1.79 21.60 ± 2.63 
4.00 23.23 ± 1.75 23.77 ± 1.59 23.16 ± 2.80 
4.50 25.55 ± 2.16 25.71 ± 1.59 24.72 ± 2.00 
5.00 28.66 ± 4.03 28.18 ± 2.14 26.65 ± 2.30 
5.50 31.09 ± 4.15 29.71 ± 1.59 28.72 ± 2.31 
6.00 33.06 ± 4.17 32.27 ± 1.15 30.67 ± 2.76 
6.50 36.12 ± 4.70 34.48 ± 0.95 31.80 ± 2.84 
7.00 38.94 ± 4.57 36.70 ± 1.29 33.41 ± 3.18 
7.50 40.90 ± 4.67 38.82 ± 1.87 35.02 ± 2.70 
8.00 43.46 ± 5.25 41.15 ± 2.65 36.89 ± 3.23 
8.50 45.43 ± 4.88 43.32 ± 3.05 38.64 ± 3.41 
9.00 49.24 ± 5.47 45.23 ± 2.68 40.28 ± 3.72 
9.50 51.01 ± 4.62 47.27 ± 2.70 41.69 ± 4.14 
10.0 52.09 ± 3.43 49.31 ± 2.95 43.47 ± 3.64 
10.5 54.16 ± 3.69 51.61 ± 2.68 45.62 ± 3.23 
11.0 56.37 ± 3.52 54.29 ± 2.83 48.26 ± 2.80 
11.5 59.23 ± 1.57 56.25 ± 2.10 50.66 ± 1.76 
12.0 59.78 ± 1.45 58.93 ± 1.71 53.33 ± 1.33 
 
*
n = 3 
 Table 11 
EXVIVO PERMEABILITY STUDY OF BENAZEPRIL HYDROCHLORIDE 
TRANSDERMAL PATCH AND PURE DRUG SOLUTION 
 
Time 
(Hours) 
Cumulative Amount of Drug Release (mg) 
Formulation Code 
F17   EL100 5.5%           
(with DMSO) 
F18 EL100 5.5%            
(without DMSO) 
Pure drug solution 
Mean ± SD
*
(%) Mean ± SD
*
(%) Mean ± SD
*
(%) 
1 0.254 ± 0.026 0.182 ± 0.182 0.165 ± 0.022 
2 0.292 ± 0.014 0.235 ± 0.025 0.209 ± 0.013 
3 0.355 ± 0.011 0.308 ± 0.014 0.250 ± 0.016 
4 0.463 ± 0.009 0.383 ± 0.037 0.311 ± 0.022 
5 0.497 ± 0.004 0.446 ± 0.024 0.423 ± 0.023 
6 0.527 ± 0.003 0.496 ± 0.010 0.492 ± 0.040 
7 0.555 ± 0.007 0.528 ± 0.009 0.587 ± 0.024 
8 0.610 ± 0.019 0.568 ± 0.005 0.692 ± 0.054 
9 0.654 ± 0.006 0.611 ± 0.014 0.754 ± 0.019 
10 0.764 ± 0.010 0.662 ± 0.021 0.892 ± 0.063 
11 0.861 ± 0.015 0.732 ± 0.029 1.061 ± 0.058 
12 0.931 ± 0.014 0.807 ± 0.020 1.175 ± 0.047 
 
*
n = 3 
 
 
Table 12 
KINETICS STUDY FOR DISOLUTION DATA OF BENAZEPRIL HYDROCHLORIDE TRANSDERMAL PATCHES 
 
Formulation 
code 
Zero Order First Order Higuchi Korsmeyer Peppas Hixson Crowell  
Release 
mechanism 
r
2
 K
0 
(h
-1
) r
2
 K1 (h
-1
) r
2
 KH
  
(h
-1/2
) r
2
 n r
2
 
KHC      
(h
-1/3
) 
F1 0.986 5.378 0.985 -0.047 0.998 22.54 0.990 0.580 0.986 -0.131 NFD 
F2 0.989 3.528 0.987 -0.023 0.996 14.78 0.993 0.530 0.987 -0.071 NFD 
F3 0.997 4.053 0.977 -0.027 0.987 16.60 0.962 0.577 0.951 -0.085 NFD 
F4 0.998 3.068 0.995 -0.018 0.997 12.78 0.980 0.537 0.979 -0.058 NFD 
F5 0.996 2.967 0.990 -0.017 0.986 12.51 0.981 0.592 0.963 -0.057 NFD 
F6 0.985 2.697 0.960 -0.015 0.991 11.32 0.988 0.575 0.984 -0.049 NFD 
F7 0.994 5.043 0.969 -0.050 0.985 20.87 0.968 0.559 0.958 -0.134 NFD 
F8 0.992 4.830 0.963 -0.038 0.977 19.79 0.948 0.554 0.947 -0.111 NFD 
F9 0.997 5.225 0.978 -0.038 0.987 21.43 0.978 0.721 0.953 -0.115 NFD 
F10 0.997 4.457 0.984 -0.030 0.991 18.32 0.967 0.654 0.958 -0.093 NFD 
F11 0.980 4.509 0.936 -0.022 0.977 18.17 0.952 0.734 0.947 -0.092 NFD 
F12 0.994 3.603 0.984 -0.038 0.987 14.99 0.978 0.616 0.953 -0.070 NFD 
F13 0.991 5.032 0.945 -0.033 0.965 20.45 0.951 0.645 0.931 -0.112 NFD 
F14 0.998 4.871 0.971 -0.033 0.992 19.96 0.987 0.769 0.954 -0.103 NFD 
F15 0.998 4.806 0.984 -0.030 0.994 19.82 0.989 0.715 0.966 -0.102 NFD 
F16 0.998 4.628 0.988 -0.030 0.993 19.04 0.981 0.727 0.961 -0.095 NFD 
F17 0.999 4.181 0.982 -0.027 0.994 17.14 0.971 0.645 0.958 -0.085 NFD 
F18 0.997 3.588 0.985 -0.022 0.992 14.79 0.977 0.595 0.963 -0.071 NFD 
 
NFD – NON FICKIAN DIFFUSION 
Table 13 
EXVIVO PERMEATION PARAMETERS OF BENAZEPRIL HYDROCHLORIDE TRANSDERMAL PATCHES AND 
PURE DRUG SOLUTION OBTAINED BY ANALYSES OF THE PERMEATION PROFILE 
 
Formulation code 
 
Accumulated amount at 12 
Hour (mg/cm
2
, Mean ± S.D
*
) 
 
Flux (mg/cm
2
.h) 
 
Lag Time (Hour) 
 
Permeability coefficient     
(h
-1
) 
F17 0.9312 ± 0.0148 0.05852 1.0 0.0169 
F18 0.8079 ± 0.0201 0.05373 1.1 0.0111 
Pure drug solution 1.1750 ± 0.0478 0.09228 0.9 0.0239 
 
*
n = 3 
Table 14 
STATISTICAL ANALYSIS OF CUMULATIVE AMOUNT OF DRUG PERMEATED  
Comparison Difference P value 
F17 vs F18 0.1233  P < 0.01 
F17 vs PD -0.2439 P < 0.001 
F18 vs PD -0.3671 P < 0.001 
 
95% Confidence Interval 
  
Table 15 
 
KINETICS STUDY FOR EXVIVO PERMEABILITY DATAOF BENAZEPRIL HYDROCHLORIDE                    
TRANSDERMAL PATCHES AND PURE DRUG SOLUTION 
 
 
Formulation 
code 
Zero Order First Order Higuchi Korsmeyer Peppas Hixson Crowell 
 
 
Release 
mechanism 
r
2
 
K
0 
(mg/h
-1
) 
r
2
 
K1           
(h
-1
) 
r
2
 
KH
  
(mg/h
-1/2
) 
r
2
 n r
2
 
KHC      
(h
-1/3
) 
 
F17 
0.975 1.170 0.970 -0.005 0.955 4.995 0.949 0.524 0.972 -0.019 FD 
F18 0.990 1.074 0.991 -0.005 0.979 4.554 0.989 0.604 0.990 -0.017 NFD 
 
NFD – NON FICKIAN DIFFUSION 
 
 
 
 
 Table 16 
HISTOPATHOLOGICAL STUDY OF RAT ABDOMINAL SKIN 
SAMPLE CODE OBSERVATIONS 
A(Untreated skin) Skin with inter muscular oedema, inflammatory cell infiltrate 
B(Skin treated with PBS P
H
7.4) Skin with fatty tissue and sparse inflammatory cell infiltrate 
C(Skin treated with Benazepril    
Hydrochloride pure drug solution) 
Skin with inflammatory cell infiltrate in the subcutaneous fat 
and oedema 
D(Skin treated with transdermal patch    
containing EL100 5.5% with DMSO) 
Skin with oedema with sparse inflammatory cell infiltrate 
E(Skin treated with transdermal patch    
containing ES100 5.5% with DMSO) 
Skin with oedema and dense inflammatory cell infiltrate 
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   FIGURE 1 DETERMINATION OF λmax OF BENAZEPRIL HYDROCHLORIDE IN                        
                      PHOSPHATE BUFFERED SALINE OF pH 7.4 
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   FIGURE 2 CALIBRATION CURVE FOR BENAZEPRIL HYDROCHLORIDE                                           
            USING PHOSPHATE BUFFERED SALINE OF P
H
 - 7.4 
 
FORMULATION CODE
W
E
I
G
H
T
 
(
m
g
)
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 F17 F18
0
5
10
15
20
25
30
35
40
 
                                  F1-EC 2.5% (WITH DMSO)                                  F7-ES100 4.0% (WITH DMSO)                                                 F13-EL100 4.5% (WITH DMSO) 
                                  F2-EC 2.5% (WITHOUT DMSO)                          F8-ES100 4.0% (WITHOUT DMSO)                                        F14-EL100 4.5% (WITHOUT DMSO) 
                                  F3-EC 3.0% (WITH DMSO)                       F9-ES100 4.5% (WITH DMSO)                                                 F15-EL100 5.0% (WITH DMSO) 
                                  F4-EC 3.0% (WITHOUT DMSO)                    F10-ES100 4.5% (WITHOUT DMSO)                                       F16-EL100 5.0% (WITHOUT DMSO) 
                                  F5-EC 3.5% (WITH DMSO)                    F11-ES100 5.0% (WITH DMSO)                                               F17-EL100 5.5% (WITH DMSO) 
 
FIGURE 5 WEIGHT VARIATION OF ALL THE FORMULATIONS 
FORMULATION CODE
T
H
I
C
K
N
E
S
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10F11F12F13F14F15F16F17F18
0.0
0.1
0.2
0.3
0.4
 
                                  F1-EC 2.5% (WITH DMSO)                                  F7-ES100 4.0% (WITH DMSO)                                                 F13-EL100 4.5% (WITH DMSO) 
                                  F2-EC 2.5% (WITHOUT DMSO)                           F8-ES100 4.0% (WITHOUT DMSO)                                        F14-EL100 4.5% (WITHOUT DMSO) 
                                  F3-EC 3.0% (WITH DMSO)                       F9-ES100 4.5% (WITH DMSO)                                                 F15-EL100 5.0% (WITH DMSO) 
                                  F4-EC 3.0% (WITHOUT DMSO)                    F10-ES100 4.5% (WITHOUT DMSO)                                       F16-EL100 5.0% (WITHOUT DMSO) 
                                  F5-EC 3.5% (WITH DMSO)                    F11-ES100 5.0% (WITH DMSO)                                               F17-EL100 5.5% (WITH DMSO) 
 
FIGURE 6 THICKNESS OF ALL THE FORMULATION 
FORMULATIONS
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                                  F1-EC 2.5% (WITH DMSO)                                  F7-ES100 4.0% (WITH DMSO)                                                 F13-EL100 4.5% (WITH DMSO) 
                                  F2-EC 2.5% (WITHOUT DMSO)                           F8-ES100 4.0% (WITHOUT DMSO)                                        F14-EL100 4.5% (WITHOUT DMSO) 
                                  F3-EC 3.0% (WITH DMSO)                       F9-ES100 4.5% (WITH DMSO)                                                 F15-EL100 5.0% (WITH DMSO) 
                                  F4-EC 3.0% (WITHOUT DMSO)                    F10-ES100 4.5% (WITHOUT DMSO)                                       F16-EL100 5.0% (WITHOUT DMSO) 
                                  F5-EC 3.5% (WITH DMSO)                    F11-ES100 5.0% (WITH DMSO)                                               F17-EL100 5.5% (WITH DMSO) 
                                   F6-EC 3.5% (WITHOUT DMSO)                    F12-ES100 5.0% (WITHOUT DMSO)                                       F18-EL100 5.5% (WITHOUT DMSO) 
 
FIGURE 7 MOISTURE CONTENT OF ALL FORMULATION 
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  FIGURE 8A INVITRO RELEASE STUDY OF BENAZEPRIL HCL TRANSDERMAL PATCH                  
             CONTAINING ETHYLCELLULOSE -2.5% (WITH AND WITHOUT DMSO) 
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  FIGURE 8B  INVITRO RELEASE STUDY OF BENAZEPRIL HCL TRANSDERMAL PATCH                                                     
                CONTAINING ETHYLCELLULOSE -3.0 % (WITH AND WITHOUT DMSO) 
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  FIGURE 8C INVITRO RELEASE STUDY OF BENAZEPRIL HCL TRANSDERMAL PATCH                                        
                             CONTAINING ETHYLCELLULOSE -3.5 % (WITH AND WITHOUT DMSO) 
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  FIGURE 8D INVITRO RELEASE STUDY OF BENAZEPRIL HCL TRANSDERMAL PATCH                                                  
                           CONTAINING EUDRAGIT S100 4.0% (WITH AND WITHOUT DMSO)        
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   FIGURE 8E INVITRO RELEASE STUDY OF BENAZEPRIL HCL TRANSDERMAL PATCH                                        
                            CONTAINING EUDRAGIT S100 4.5% (WITH AND WITHOUT DMSO) 
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   FIGURE 8F INVITRO RELEASE STUDY OF BENAZEPRIL HCL TRANSDERMAL PATCH   
                         CONTAINING EUDRAGIT S100 5.0 % (WITH AND WITHOUT DMSO) 
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   FIGURE 8G INVITRO RELEASE STUDY OF BENAZEPRIL HCL TRANSDERMAL PATCH                                    
                          CONTAINING EUDRAGIT L100 4.5% (WITH AND WITHOUT DMSO) 
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  FIGURE 8H INVITRO RELEASE STUDY OF BENAZEPRIL HCL TRANSDERMAL PATCH                                       
              CONTAINING EUDRAGIT L100 5.0% (WITH AND WITHOUT DMSO) 
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   FIGURE 8I INVITRO RELEASE STUDY OF BENAZEPRIL HCL TRANSDERMAL PATCH                                   
              CONTAINING EUDRAGIT L100 5.5% (WITH AND WITHOUT DMSO) 
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  FIGURE 8J INVITRO RELEASE STUDY OF BENAZEPRIL HYDROCHLORIDE TRANSDERMAL    
            PATCH CONTAINING ETHYLCELLULOSE AT VARIOUS CONCENTRATIONS                                       
            (WITH PERMEATION ENHANCER) 
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  FIGURE 8K INVITRO RELEASE STUDY OF BENAZEPRIL HYDROCHLORIDE TRANSDERMAL                                     
              PATCH CONTAINING ETHYLCELLULOSE AT VARIOUS CONCENTRATIONS                                                  
              (WITHOUT PERMEATION ENHANCER) 
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   FIGURE 8L INVITRO RELEASE STUDY OF BENAZEPRIL HYDROCHLORIDE TRANSDERMAL   
              PATCH CONTAINING EUDRAGIT - S100 AT VARIOUS CONCENTRATIONS                      
              (WITH PERMEATION ENHANCER) 
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   FIGURE 8M INVITRO RELEASE STUDY OF BENAZEPRIL HYDROCHLORIDE TRANSDERMAL    
    PATCH CONTAINING EUDRAGIT - S100 AT VARIOUS CONCENTRATIONS                                                      
               (WITHOUT PERMEATION ENHANCER) 
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   FIGURE 8N  INVITRO RELEASE STUDY OF BENAZEPRIL HYDROCHLORIDE TRANSDERMAL                            
                PATCH CONTAINING EUDRAGIT – L100 AT VARIOUS CONCENTRATIONS                                         
                (WITH PERMEATION ENHANCER) 
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   FIGURE 8O INVITRO RELEASE STUDY OF BENAZEPRIL HYDROCHLORIDE TRANSDERMAL                             
               PATCH CONTAINING EUDRAGIT – L100 AT VARIOUS CONCENTRATIONS                                          
               (WITHOUT PERMEATION ENHANCER) 
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  FIGURE 9A COMPARISON OF ZERO ORDER RELEASE KINETICS OF THE FORMULATIONS   
             CONTAINING ETHYLCELLULOSE AT VARIOUS CONCENTRATIONS                                                                  
             (WITH AND WITHOUT DIMETHYL SULFOXIDE) 
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  FIGURE 9B COMPARISON OF FIRST ORDER RELEASE KINETICS OF THE FORMULATIONS                           
             CONTAINING ETHYLCELLULOSE AT VARIOUS CONCENTRATIONS                                                                
             (WITH AND WITHOUT DIMETHYL SULFOXIDE) 
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  FIGURE 9C COMPARISON OF HIGUCHI RELEASE KINETICS OF THE FORMULATIONS                                      
                        CONTAINING ETHYLCELLULOSE AT VARIOUS CONCENTRATIONS                                                                  
                        (WITH AND WITHOUT DIMETHYL SULFOXIDE) 
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  FIGURE 9D COMPARISON OF KORSMEYER AND PEPPAS RELEASE KINETICS OF THE                                   
                         FORMULATIONS CONTAINING ETHYLCELLULOSE AT VARIOUS CONCENTRATIONS                              
                         (WITH AND WITHOUT DIMETHYL SULFOXIDE) 
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  FIGURE 9E COMPARISON OF HIXSON-CROWELL RELEASE KINETICS OF THE FORMULATIONS                      
                        CONTAINING ETHYLCELLULOSE AT VARIOUS CONCENTRATIONS                                                                  
                        (WITH AND WITHOUT DIMETHYL SULFOXIDE) 
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                                (WITH AND WITHOUT DIMETHYL SULFOXIDE) 
 
TIME IN HO URS
L
O
G
 
C
U
M
U
L
A
T
I
V
E
 
%
 
D
R
U
G
 
R
E
M
A
I
N
I
N
G
0 2 4 6 8 10 12 14
0.0
0.5
1.0
1.5
2.0
2.5
F7 ES 100 4.0% (WITH DMSO) F8 ES 100 4.0% (WITHO UT DMSO ) F9 ES 100 4.5% (WITH DMSO )
F10 ES 100 4.5% (WITHO UT DMSO ) F11 ES 100 5.0% (WITH DMSO ) F12 ES100  5.0% (WITHO UT DMSO )
 
  FIGURE 9G COMPARISON OF FIRST ORDER RELEASE KINETICS OF THE FORMULATIONS                                    
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  FIGURE 9H COMPARISON OF HIGUCHI RELEASE KINETICS OF THE FORMULATIONS                                       
                                    CONTAINING EUDRAGIT S 100 AT VARIOUS CONCENTRATIONS                                                                       
                                    (WITH AND WITHOUT DIMETHYL SULFOXIDE) 
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   FIGURE 9I COMPARISON OF KORSMEYER AND PEPPAS RELEASE KINETICS OF                         
              THE FORMULATIONS CONTAINING EUDRAGIT S 100 AT VARIOUS                      
              CONCENTRATIONS (WITH AND WITHOUT DIMETHYL SULFOXIDE) 
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  FIGURE 9J COMPARISON OF HIXSON-CROWELL RELEASE KINETICS OF                                                                             
                        THE FORMULATIONS CONTAINING EUDRAGIT S 100 AT VARIOUS                                                           
             CONCENTRATIONS (WITH AND WITHOUT DIMETHYL SULFOXIDE) 
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   FIGURE 9K COMPARISON OF ZERO ORDER RELEASE KINETICS OF THE                                                           
               FORMULATIONS CONTAINING EUDRAGIT L 100 AT VARIOUS                                                                
               CONCENTRATIONS (WITH AND WITHOUT DIMETHYL SULFOXIDE) 
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   FIGURE 9M COMPARISON OF HIGUCHI RELEASE KINETICS OF THE                                                                
                           FORMULATIONS CONTAINING EUDRAGIT L 100 AT VARIOUS                                                               
                           CONCENTRATIONS (WITH AND WITHOUT DIMETHYL SULFOXIDE) 
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   FIGURE 9N COMPARISON OF KORSMEYER AND PEPPAS RELEASE KINETICS OF                                                  
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                                     CONCENTRATIONS (WITH AND WITHOUT DIMETHYL SULFOXIDE) 
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   FIGURE 10A  COMPARISION OF EXVIVO PERMEABILITY STUDY BENAZEPRIL                                                      
                  HYDROCHLORIDE TRANSDERMAL PATCHES WITH PURE DRUG SOLUTION 
 
 
    FIGURE 10B EXVIVO PERMEABILITY STUDY OF BENAZEPRIL HYDROCHLORIDE                                            
                TRANSDERMAL PATCH CONTAINING EUDRAGIT L 100 5.5% (WITH DMSO) 
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    FIGURE 10C EXVIVO PERMEABILITY STUDY OF BENAZEPRIL HYDROCHLORIDE   
                 TRANSDERMAL PATCH CONTAINING EUDRAGIT L 100 5.5% (WITH OUT DMSO) 
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 FIGURE 10D EXVIVO PERMEABILITY STUDY OF BENAZEPRIL HYDROCHLORIDE PURE DRUG SOLUTION 
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  FIGURE 11A  COMPARISON OF ZERO ORDER EXVIVO PERMEABILITY RELEASE KINETICS OF  
                 FORMULATIONS CONTAINING EUDRAGIT L 100 5.5% (WITH AND WITHOUT DMSO) 
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  FIGURE 11B  COMPARISON OF FIRST ORDER EXVIVO PERMEABILITY RELEASE KINETICS OF  
                FORMULATIONS CONTAINING EUDRAGIT L 100 5.5% (WITH AND WITHOUT DMSO) 
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  FIGURE 11C  COMPARISON OF HIGUCHI EXVIVO PERMEABILITY RELEASE KINETICS OF   
                            FORMULATIONS CONTAINING EUDRAGIT L 100 5.5% (WITH AND WITHOUT DMSO) 
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   FIGURE 11D  COMPARISON OF KORSMEYER AND PEPPAS EXVIVO PERMEABILITY RELEASE  
                             KINETICS OF FORMULATIONS CONTAINING EUDRAGIT L 100 5.5%                                
                  (WITH AND WITHOUT DMSO) 
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   FIGURE 11E  COMPARISON OF HIXSON-CROWELL EXVIVO PERMEABILITY RELEASE   
                                        KINETICS OF FORMULATIONS CONTAINING EUDRAGIT L 100 5.5%                                
                  (WITH AND WITHOUT DMSO) 
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